Cloning and Characterization of a Novel Phospholipase C Enzyme, Human Phospholipase C Eta2 by Zhou, Yixing
Cloning and Characterization of a Novel Phospholipase C Enzyme, Human 
Phospholipase C Eta2 
Yixing Zhou 
A dissertation submitted to the faculty of the University of North Carolina at Chapel 
Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in 
the Department of Pharmacology. 
Chapel Hill 
2007 
 
Approved by: 
Advisor: Professor T. Kendall Harden 
Reader: Professor Jose L. Boyer 
Reader: Professor Alan M. Jones 
Reader: Professor Robert A. Nicholas 
Reader: Professor John E. Sondek 
 ii
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2007 
Yixing Zhou 
ALL RIGHTS RESERVED 
 iii
ABSTRACT 
 
Yixing Zhou 
Cloning and Characterization of a Novel Phospholipase C Enzyme, Human 
Phospholipase C Eta2 
(Under the direction of Dr. T. Kendall Harden) 
 
G-protein-coupled receptors are cell surface macromolecules that regulate 
numerous cell physiologies through activation of the heterotrimeric G proteins. One 
very important signaling pathway downstream of heterotrimeric G protein is the 
hormone-activated phospholipase C pathway. Proteins of the 
phosphoinositide-specific phospholipase C (PLC) family play important roles in cell 
signaling. In response to numerous extracellular stimuli, such as neurotransmitters, 
hormones and growth factors, PLC catalyzes the hydrolysis of phosphatidylinositol 
(4,5)bisphosphate (PtdIns(4,5)P2) to generate two well-established second 
messengers, inositol(1,4,5)trisphosphate and diacylglycerol, and thereby increasing 
intracellular Ca2+ concentration and activating protein kinase C. These cellular 
signaling events eventually lead to a number of cellular responses such as 
neurotransmission, cardiac- and smooth muscle-contraction and blood pressure 
regulation. In addition to the hormone receptor activation of PLC, receptor tyrosine 
kinases, non-receptor tyrosine kinases, and members of the Ras superfamily 
GTPases also utilize PLC to regulate important cell physiologies. Moreover, 
PtdIns(4,5)P2 has been increasingly realized to be an important molecule that 
interacts with a broad range of signaling proteins. By altering ratio of PtdIns(4,5)P2, 
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PLC potentially affects membrane association and activity of many signaling proteins. 
Therefore, PLC is a key enzyme in normal cell physiology. 
The work described herein reports the indentification, molecular cloning and 
characterization of a novel PLC isozyme, PLC-η2. First, I cloned PLC-η2 from human 
retina cDNA, and I examined possible existence of splice variants of the gene. Next I 
studied potential regulation of PLC-η2 by heterotrimeric G proteins and several 
members of the Ras family. Finally, I purified enzymes to homogeneity and 
demonstrated enzyme activity and direct activation in phospholipid vesicls. The work 
presented here expands further complexity and interplay between different PLC 
isozymes and possibly their regulatory networks.
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CHAPTER 1 
INTRODUCTION 
 
1.1 Cell Signaling 
Living organisms coordinate their activities, almost at every level, through signal 
transduction by chemical complexes. These chemical complexes, which include cell 
surface receptors and intracellular macromolecules, constitute delicate and precise 
signaling systems. To achieve growth, metabolism, and reproduction, living cells 
“invented” a language to communicate with the extracellular environment, within the 
cell, and among the cells. Whether the cell migrates, or commits to neuronal 
differentiation, or metabolizes nutrients, or secretes hormones, every living cell 
constantly receives stimuli, “talks” to intracellular enzymes, and eventually produces 
a physiological response. The cellular network is analogous to a complex mechanical 
clock. The challenge is to find the “mechanical parts” within the cell and understand 
the language cells use to transmit signals that generate the end responses we 
observe. Understanding the basics of cellular functions is an essential step for 
development of approaches to rectify abnormal cell functions. 
1.2 G-Protein-Coupled Receptor Signaling Pathways and Their Physiological 
Significance 
There are many different types of cell signaling responses or pathways. Signaling 
through G-protein-coupled receptors (GPCRs) and heterotrimeric G proteins 
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represents a very important type of signaling. With more than 800 members, GPCRs 
represent by far the largest and most diverse family of cell surface proteins involved 
in signal transduction (1). They account for greater than 2% of the total genes 
encoded by the human genome. These receptors control multitudes of physiological 
events, including neurotransmission, hormonal regulation and release from autocrine 
and paracrine loops, cardiac- and smooth-muscle contraction, blood pressure 
regulation, etc. Defects or dysfunction at the receptor level is related to many human 
diseases. Directly or indirectly, more than 40% of all current therapeutic agents target 
G-protein-coupled receptors at the molecular level (2). 
GPCRs all share a common core composed of seven transmembrane helical 
domains with an N-terminus and three intervening segments between the 
transmembrane domains facing the extracellular environment and three intervening 
segments and a C-terminus facing the cytosolic milieu (3). GPCRs sense 
extracellular stimuli and transduce the signal inside the cell to govern numerous 
cellular events. This signal transduction pathway is comprised of three major 
components, GPCR, heterotrimeric G proteins, and effector molecules. Members of 
the GPCR family include those for hormones, neurotransmitters, chemokines and 
cytokines, peptides, lipids, Ca2+ ions, odorants, sweet and bitter tastes, photons of 
light, etc (1). A wide range of small molecule drugs have been developed that bind to 
GPCRs, acting either as agonists, antagonists, or inverse agonists. The 
heterotrimeric G proteins belong to the superfamily of GTPases highly conserved 
from prokaryotes to mammals. They are composed of three polypeptides, designated 
α, β, and γ, with the α subunit containing both the GTP-binding and GTPase activity. 
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Heterotrimeric G proteins transduce signals to effector proteins such as adenylyl 
cyclase, phospholipase C, cGMP phosphodiesterase, PI3K, ion channels, tyrosine 
kinase, and MAP kinase to elicit physiological responses (3). 
At the resting state, GPCRs are in an inactive conformation and guanine 
nucleotide diphosphate (GDP) is bound to Gα, which is in a high affinity complex with 
membrane bound Gβγ. Receptors are activated by agonist-promoted changes in their 
conformation and consequentially act as guanine nucleotide exchange factors (GEFs) 
to promote the release of GDP and association of guanine nucleotide triphosphate 
(GTP) on Gα. GTP bound Gα changes its conformation at three switch regions 
resulting in decreased affinity for Gβγ, and therefore, Gα and Gβγ dissociate and 
stimulate their respective downstream effectors (3;4) (Figure 1.1). Gα subunits 
possess intrinsic GTPase activity that slowly hydrolyzes GTP to GDP to allow 
re-association with Gβγ, completing the G protein activation cycle (Figure 1.1). Some 
downstream effectors, such as phospholipase C-β1, act as GTPase accelerating 
proteins (GAPs) to terminate the G protein cycle (5;6). More importantly, a large 
group of proteins, termed regulators of G-protein signaling (RGS) proteins, possess 
GAP activity toward various Gα subunits. Hence, the cycle of GPCR/G protein 
signaling is tightly and precisely regulated to ensure normal physiological functions. 
Mutations in genes that encode GPCRs and G proteins can lead to either 
gain-of-function or loss-of-function by impairing multiple steps in the GPCR/G protein 
signaling cycle. For example, mutations in transducin (Gαt) have been associated 
with autosomal dominant stationary night blindness; activating Gαs mutations on 
Arg201 and Gln227 are linked with pituitary adenomas, thyroid, parathyroid and 
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adrenal tumors, fibrous dysplasia (FD) of bone, and McCune-Albright syndrome 
(MAS); inactivating Gαs mutations are linked to peudohypoparathyroidism; Gβ3 
polymorphism with a single base pair substitution initially links with hypertension and 
may contribute in metabolic syndromes; GPCR loss-of-function mutations lead to 
hormonal dysregulation, developmental anomalies, blindness, etc; GPCR 
gain-of-function mutations result in hormonal dysregulation, sporadic tumors, 
abnormal bone development, hypocalcemia and hypercalcuria, etc (2). Hence, 
aberrations at the gene level of either the receptor or G protein have led to numerous 
human diseases. Studies defining structure-function relationships of G proteins and 
GPCRs have shed light on the fundamental basis of some disease mechanisms. For 
example, the crystal structures of Gαt with AlF4- bound (mimicking the activating state 
of Gαt) provided molecular basis of a pentavalent geometry that stabilizes the 
intermediate state of GTP hydrolysis (7) (see section 1.2.1 for details). An activating 
mutation of Gα at a conserved residue (such as Gln 200 in Gαt) essential for GTPase 
activity that fails to stabilize the intermediate state would render the resulting Gα 
constitutively active. Interference with GPCRs and their downstream targets likely will 
continue to provide opportunities for the development of new and mechanism-based 
strategies for disease diagnosis, prevention and treatment in the near future. 
1.2.1 Heterotrimeric G Proteins: Gα Subunit 
There are four subfamilies and a total of 17 Gα subunits, Gαs (Gαs-short, Gαs-long, 
Gαolf), Gαi (Gαi1-3, GαoA-oB, Gαt, Gαz), Gαq (Gαq, Gα11, Gα14, Gα15-16) and Gα12/13. 
Gαs stimulates adenylyl cyclase resulting in increasing levels of cyclic AMP (cAMP), 
whereas Gαi inhibits adenlyl cyclase resulting in lower cAMP levels. The members of 
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the Gαq family bind to and activate phospholipase C (PLC), which cleaves 
phosphatidylinositol(4,5)bisphosphate (PtdIns(4,5)P2) into diacylglycerol and 
inositol(1,4,5)trisphosphate (Ins(1,4,5)P3).  
Cholera toxin catalyzes ADP-ribosylation of Gαs, which inhibits intrinsic GTPase 
activity, whereas the pertussis toxin catalyzes ADP-ribosylation of the Gαi isoforms 
on a C-terminal cysteine, which uncouples Gα from its activating receptors (4). The 
members of the Gαq subfamily are not substrates for either of the two toxins. Gαq and 
Gα11 have a wide tissue distribution, whereas Gα14 and Gα16 are expressed more 
restrictively in stromal, epithelial, and hematopoietic cells (3). Gα12/13 proteins are 
widely expressed and resistant to both toxins. They transform fibroblasts when 
overexpressed (8), participate in P19 stem cell differentiation in response to retinoic 
acid (9), and activate the mitogen-activated protein kinases (MAPK) especially the 
Jun kinase (10). Among the many reported effectors, guanine nucleotide exchange 
factors for Rho (RhoGEFs) are the only confirmed direct effectors of Gα12/13. The 
prototypical member of this family is p115RhoGEF, which contains a Dbl homology 
(DH) domain that regulates the activity of Rho family proteins. p115RhoGEF also 
contains an RGS domain that specifically binds to Gα12/13, but not Gαq or Gαi, and 
enhances the GTPase activity of Gα12/13 by stabilizing the transition state of the Gα 
subunits (11). Other RhoGEFs include LARG, PDZ-RhoGEF, and GTRAP48. 
The Gα subunit is structurally composed of two domains, a Ras-like GTPase 
domain and a helical domain unique to each Gα. Figure 1.2a represents a crystal 
structure of Gαi1 in complex with GDP in the presence of Mg2+ (adopted from 
reference (12) with minor modification). Many other crystal structures of Gαs, Gαt, or 
 6
Gαi1, in complex with different guanine nucleotides are available (7;13-18). The 
GTPase domain contains three switch regions (switch region I, II, and III) which 
change conformation according to the guanine nucleotide-liganded state of Gα. The 
guanine nucleotide binds in a deep cleft flanked by the GTPase and helical domain, 
making direct interactions with the GTPase domain only. The switch regions are more 
ordered when Gα is GTP-bound making contacts with the γ-phosphate of GTP, 
whereas they are more flexible in Gα·GDP (15). 
Aluminum tetrafluoride (AlF4-) activates the Gα subunit by binding to Gα·GDP 
occupying the γ-phosphate position in Gα·GTP. The crystal structure of 
AlF4--activated Gαt (Gαt·GDP·AlF4-·H2O) revealed a geometry at the nucleotide 
binding pocket, resembling the pentavalent intermediate of GTP hydrolysis (Figure 
1.2b is adopted from reference (7) with minor modification). AlF4- not only makes 
contacts with residues that interact with the γ-phosphate in Gαt·GTP but also forms 
hydrogen bonds with conserved residues (Thr 177 and Gln 200) essential for 
GTPase activity of Gαt. This molecular coordination stabilizes the high energy state 
of the pentavalent intermediate of GTP hydrolysis. Hence, GAPs accelerate the rate 
of hydrolysis by rearranging key residues in a similar manner as above to stabilize the 
intermediate state. Mutations in the key residues essential for GTPase activity, such 
as those equivalent for Gln 200 and Gly 38 in Gαt, cause a drastic reduction in the 
intrinsic GTPase activity leading to constitutive activation of the Gα subunit. 
1.2.2 Heterotrimeric G Proteins: Gβγ Subunit 
G protein βγ subunits were originally thought to principally function as negative 
regulators of the activity of Gα subunits. However, the discovery of Gβγ 
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subunit-mediated activation of the muscarinic K+ channel (G protein-coupled 
inwardly-rectifying potassium channels (GIRKs, Kir3.x)) by Logothetis, Neer, and 
Clapham in 1987 fundamentally shifted this paradigm (19). Numerous Gβγ effectors 
have been subsequently identified (20;21), including adenylyl cyclase (AC) (22), PLC 
(23), phospholipase A2 (PLA2) (24), phosphoinositide 3-kinase (PI3K) (25), 
β-adrenergic receptor kinase (βARK or GRK) (26), p21ras (Ras) mediated 
mitogen-activated kinase (MAP) pathway (27), Ras exchange factor CDC25Mm or 
p140Ras-GRF (28), N- and P/Q-type Ca2+ channel (29), T-type calcium channel (30), 
Rac-specific guanine nucleotide exchange factor (P-Rex1) (31-33); and this list keeps 
expanding. 
There are five Gβ subunits (Gβ1, β2, β3, β4, and β5) and β1, β2, β3, and β4 share 
greater than 80% sequence identity. In contrast, Gβ5 shares 53% identity with other 
Gβ subunits. Gβ subunits are widely expressed in tissues. There are twelve different 
Gγ subunits and their sequence identities are more variant than is the case with Gβ 
subunits. Gγ1 is expressed only in retina and Gγ2 and Gγ3 are highly expressed in 
brain; whereas other Gγ subunits have wide tissue distributions. 
Gβ and Gγ subunits function in an obligate heterodimeric complex. Gβ is 
composed of a 20 amino acid α helix at its amino terminus and the remaining 300 
amino acids comprise seven WD repeats made up of antiparallel β strands (16) 
(Figure 1.3). The crystal structure of Gβ has revealed a propeller topology with seven 
blades each made of twisted β strands. The WD repeats are found in many proteins, 
and these proteins are involved in diverse cellular signaling pathways (34). The 
WD-repeat is composed of a variable sequence bounded by highly conserved 
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residues Gly-His (GH) and Trp-Asp (WD). Gγ subunits contain amino terminal α 
helices that interact with the amino terminus of Gβ subunits, α helices region that 
makes contacts with Gβ blades 5, 6, and 7, and a variable carboxyl terminal region 
that interacts with the membrane (16) (Figure 1.3). The carboxyl terminus of the Gγ 
subunits contains a CAAX box and these proteins exist in prenylated forms in cells. 
Gγ1, γ8, and γ11 are covalently modified with the 15-carbon farnesyl group, and Gγ2, γ3, 
γ4, γ5, γ7, γ9, γ10, γ12, and γ13 are modified with the 20-carbon geranylgeranyl group (35). 
The lipid modification mediates association of Gγ subunits, and therefore, Gβγ, with 
membranes (36). 
 Gα binds asymmetrically with Gβ making contacts with residues in blades 1, 2, 
and 3 (14). The switch-II region of Gα positions over the central tunnel of Gβ. 
Numerous studies have shown that mutagenesis of residues in Gβ known from the 
crystal structure to contact Gα have inhibitory effects on the capacity of Gβγ to 
activate either PLC-β2 or PLC-β3, which suggests that Gα subunits and Gβγ effectors 
use similar binding surfaces for Gβγ subunit interaction. 
1.2.3 RGS Proteins 
RGS proteins were discovered in 1996 as a new family of Gα GAPs (37-41). RGS 
proteins contain a canonical, roughly 120 amino acid RGS domain that interacts with 
Gα in its switch region, stabilizes the transition state of GTP hydrolysis, and therefore, 
accelerates the enzymatic reaction. Crystal structures of RGS4 in complex with 
Gαi·GDP·AlF4- and RGS9 in complex with Gαt·GDP·AlF4- have revealed many 
insights into the molecular mechanism of GTPase activity (42;43). As key negative 
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regulators of G protein signaling pathways, RGS proteins are potentially important 
drug targets. 
1.3 Second Messengers Inositol Phosphates and Diacylglycerol Signaling and 
Their Implications 
Cell surface receptors and heterotrimeric G proteins trigger activation of 
phospholipase C (PLC) enzymes to hydrolyze the minor membrane lipid 
PtdIns(4,5)P2 into the Ca2+-mobilizing second messenger, Ins(1,4,5)P3, and the 
protein kinase C-activating second messenger, diacylglycerol (DAG) (Figure 1.4). 
These second messenger signaling responses control biological processes ranging 
from many classically defined physiological responses such as platelet shape 
change/aggregation and smooth muscle contraction to processes at the heart of cell 
biology including the regulation of cell fertilization, cell growth, division, differentiation, 
and chemotaxis. 
1.3.1 History of Inositol Phosphates and Calcium Signaling 
The original demonstration of receptor stimulated lipid turnover in 1953 by Hokin 
and Hokin (44) occurred serendipitously. They treated pancreatic slices with 
acetylcholine to investigate 32P incorporation into RNA. However, no radioactivity was 
observed incorporated into RNA, but instead most of the radioactivity was found in 
inositol lipids and phosphatidic acid. In the next decade, PtdIns(4,5)P2 was purified 
from cow brain with contributions from many scientists (Jordi Folch, Dittmer and 
Dawson, and Brown and Stewart); PI-specific PLC that hydrolyzes phosphoinositol 
lipids was successfully isolated by Thompson and Dawson (45). Durell and 
co-workers in 1969 first placed inositol lipid metabolism immediately downstream of 
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receptor activation (46). This concept was expanded and crystallized by Robert 
Michell in 1975 who hypothesized a causal link between inositol lipid metabolism and 
changes in Ca2+ homeostasis (47). Berridge and Fain provided the first direct 
evidence for this seminal milestone in 1979 (48). After prolonged receptor stimulation 
of the blowfly salivary gland, they observed that the calcium response was lost. 
However, when they supplied the blowfly salivary gland with inositol, the lost calcium 
response was restored to normal level, suggesting that inositol lipid metabolism 
resulted in Ca2+ responses. 
Michell et al. confirmed in 1981 that PtdIns(4,5)P2 was a principal substrate for 
receptor-activated PI-PLC (49). Ins(1,4,5)P3 was illustrated to be the first and the 
principal inositol phosphate formed from receptor-stimulated inositol lipid hydrolysis 
(50;51). Moreover, Streb et al. in 1983 (52) were the first to show Ins(1,4,5)P3 
mobilizes Ca2+ from stores in the endoplasmic reticulum (ER), and thus illustrated 
that this immediate metabolite of PtdIns(4,5)P2 hydrolysis functions as a second 
messenger that is generated by receptor activation and regulates intracellular Ca2+. 
The Ins(1,4,5)P3 receptor was subsequently identified and cloned (53-55). Its 
localization on the ER consolidated the status of Ins(1,4,5)P3 as a Ca2+-mobilizing 
agent.  
Nishizuka and colleagues in 1979 discovered protein kinase C (PKC) and 
proposed that PKC could be regulated in vivo by DAG (56). Soon after, Berridge in 
1984 realized DAG and Ins(1,4,5)P3 are both second messengers that are generated 
from one enzymatic reaction by PI-PLC (57). Second messengers are defined as 
molecules that are rapidly produced, act at low concentrations, and are removed by 
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specific mechanisms. As mentioned above, Ins(1,4,5)P3 is rapidly produced upon 
receptor stimulation and causes Ca2+ release from ER. Ins(1,4,5)P3 is then 
metabolized by several inositol phosphatases. The enzymatic reaction of PI-PLC 
produces DAG which in turn activates PKC with Ca2+ and phosphatidylserine as 
cofactors. DAG is then converted to phosphatidic acid or monoacylglycerol and 
arachidonic acid. Both the release of Ca2+ and activation of PKC lead to many cellular 
responses. Arachidonic acid, one metabolite of DAG, and its metabolites 
(prostaglandins, leukotrienes, thromboxanes, and prostacyclins, collectively referred 
as eicosanoids) can further activate guanylate cyclase to produce intracellular cGMP. 
Capacitative Ca2+ entry was a mechanism first hypothesized by Jim Putney to 
explain entry of extracellular Ca2+ as a direct consequence of the intracellular Ca2+ 
release from ER (58). The molecular components were identified with the discovery 
of Stim and Orai proteins (59-61). The current working model of capacitative Ca2+ 
entry involves Stim1 sensing the Ca2+ concentration changes inside the ER and 
redistributing within ER to near Orai1 protein residing at the plasma membrane and 
thereby activating Orai in an unknown mechanism (62).  
It is noteworthy to mention a major breakthrough in Ca2+ studies in the early 
1980s that made numerous studies possible. That is, the ability to measure dynamic 
intracellular Ca2+ concentrations. Although the first measurement of changes in 
intracellular Ca2+ occurred in 1966, the major revolution came with the invention of 
fluorescent Ca2+ dyes by Roger Tsien in 1982 (63). These dyes are easily loaded into 
intact cells as acetoxymethyl esters, and increasingly powerful approaches for Ca2+ 
imaging have been developed. 
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1.3.2 The Evolving Physiological Significance of Inositol Lipids 
Although PtdIns(4,5)P2 represents roughly 1% of total cellular phospholipids, this 
polyphosphoinositide directly affects an astonishing variety of fundamental cellular 
processes. Its biosynthesis and metabolism have been reported to regulate actin 
cytoskeleton (64), membrane trafficking, endocytosis and exocytosis (65;66), and ion 
channel activity (67). PtdIns(4,5)P2 is mainly generated through the phosphorylation 
of phophatidylinositol-4-phosphate by phosphoinositide phosphate 5-kinase (PIP5K). 
PtdIns(4,5)P2 is generally believed to be present in confined regions, for example in 
lipid rafts, to control specific cellular functions, rather than randomly distributed in 
cells (68). Therefore, the de novo synthesis and turnover of the lipid in a particular 
subcellular compartment is believed to be tightly and distinctly regulated, especially 
by monomeric GTPases (64). PtdIns(4,5)P2 is not only consumed by PLC-mediated 
hydrolysis, but also can be further phosphorylated by PI3K to PI(3,4,5)P3, which also 
plays an important role in actin remodeling, mitogenesis and cell survival. 
PtdIns(4,5)P2 is metabolized by dephosphorylation via inositol polyphosphate 
5-phosphatases, which are believed to control local PtdIns(4,5)P2 concentrations and 
are responsible for PtdIns(4,5)P2 recycling during vesicle trafficking. Organized 
PtdIns(4,5)P2 turnover is apparently critical for regulated secretion, but also affects 
phagocytosis as well as neurite formation. 
Inositol lipids specifically interact with proteins containing unique 
phosphoinositide-binding domains, including conserved pleckstrin homology (PH), 
phox homology (PX), FYVE, FERM, ENTH and other domains (69;70). The activity of 
many proteins is regulated by the concentration of PtdIns(4,5)P2 in the membrane, 
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and therefore, PLC-catalyzed decreases in PtdIns(4,5)P2 levels cause dramatic 
signaling responses independent of the production of the second messengers. For 
example, PtdIns(4,5)P2 directly increases activity of ion channels such as the 
Na+-Ca2+ exchanger, and the ATP-sensitive potassium channel (67). Localized 
depletion of PtdIns(4,5)P2 releases cofilin to promote early and transient actin 
barb-end formation necessary for lamellipodia and directional membrane protrusion 
(71). In summary the spatial and temporal regulation of different polyphosphoinositide 
pools plays an important role in controlling membrane association and the activity of 
a broad range of signaling proteins. 
PtdIns(4,5)P2 exhibits a nuclear localization in addition to its localization at the 
plasma and other membranes (72;73). Consistent results from an extensive literature 
concerning nuclear PI-PLC have shown that PLC-β1 is present at the nucleus and 
generates DAG. Lucio Cocco and coworkers have suggested that ERK activation by 
extracellular stimuli such as IGF-1 can phosphorylate PLC-β1 on Ser982 (74;75). 
Although no obvious increase in PLC-β1 enzymatic activity occurs as the result of this 
phosphorylation, a Ser982Ala mutant of PLC-β1 functions as a dominant-negative on 
IGF-1 mediated cell growth. Another Ser982Ala mutant that does not localize to the 
nuclei does not have such effect. Shuttling of PLC-δ1 between the nucleus and the 
cytoplasm has been observed as well. The downstream signaling molecules 
generated by nuclear PI-PLC, DAG and inositol lipids have been implicated in 
chromatin remodeling, G1-S transition, and G2-M transition (76). 
1.4 Phospholipase C Enzymes 
The phospholipase C (PLC) signaling pathway has a long history that began in 
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1953 with the work of Hokins (44). However, the PLC field became well established in 
the mid-1990s at the molecular level with the cloning and purification of the PLC 
isozymes responsible for the second-messenger production. 
1.4.1 PLC Isozymes 
A large and diverse family of PLC isozymes exists with a common role of 
regulating membrane phospholipid metabolism. They include six subfamilies of PLC 
(PLC-β, -γ, -δ, -ζ, -ε and -η) and a total of thirteen members. Two catalytically inactive 
species, termed PLC-L1 and PLC-L2, were identified but are not included in the 
above classification. The family of PLC isozymes initially included PLC-β, PLC-γ and 
PLC-δ (PLC-α was realized to be a proteolytic fragment of PLC-δ1) (77). However, 
within the past half decade, the mammalian family of PLC has expanded to include 
PLC-ε, PLC-ζ, and PLC-η. All eukaryotic PLC isozymes require calcium ions for their 
catalytic activity (discussed in detail in section 1.4.3). 
PLC isozymes exhibit different mechanisms in their responses to hormonal 
stimulation of cell surface receptors. For example, receptor tyrosine kinases enhance 
PtdIns(4,5)P2 hydrolysis by phosphorylating and activating PLC-γ in a wide variety of 
cells in response to epidermal growth factor (EGF), platelet-derived growth factor 
(PDGF), fibroblast growth factor (FGF), nerve growth factor (NGF), vascular 
endothelial growth factor, glial cell-derived growth factor, and hepatocyte growth 
factor (78). Gαq- and Gβγ- subunits of heterotrimeric G proteins induce PLC-β 
activation in response to stimulation of a wide variety of G-protein coupled receptors 
by nucleotides, neurotransmitters, chemoattractants and hormones (77). The recent 
discovery of regulation of PLC, specifically PLC-β2, PLC-γ2 and PLC-ε, by Ras 
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superfamily of small GTPases added enormous complexity in the field of PLC 
regulation (79-81). With the discovery of the novel subfamily members, PLC-η, 
through mammalian genome mining (82-85), which ostensibly has completed the 
entire family, it is now important to delineate the functions of each PLC isoforms, to 
describe the diverse functions of PtdIns(4,5)P2, to understand the spatial and 
temporal regulation of inositol lipid signaling, and to define the mechanism of 
activation of PLC at the structural level. 
1.4.2 Canonical Domain Structure of PLC Isozymes 
PLC isozymes exhibit relatively low overall homology, but each PLC isozyme 
contains a conserved catalytic core of the enzyme (Figure 1.5). The canonical 
domain structure includes a pleckstrin homology domain, EF (elongation factor)-hand 
repeats, catalytic TIM (triose phosphate isomerase) barrel, and C2 domain. Amino 
acid sequences of sixteen PLC isozymes (encompassing all forms of PLC) are 
aligned using ClustalX (see Appendix). Each domain is indicated and the results of 
the sequence alignment are illustrated by the phylogenetic tree (Figure 1.6). 
1.4.2.1 PH Domain 
The pleckstrin homology domain (PH) was initially identified at the N and C 
termini of pleckstrin, a major substrate of PKC in platelets (86-88). PH domains are 
100-120 residue sequences found in a large number of proteins, from yeast to 
mammals. It ranks as the 11th and 17th most common domain in human and yeast, 
respectively (89;90).  
A conserved structural motif exists among the PH domains whose structures 
have been determined by x-ray diffraction and NMR studies. These domains possess 
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an almost identical core β-sandwich structure capped with a carboxyl-terminal α-helix 
at one corner. The loops between the β strands, particularly the β1/β2, β3/β4, and 
β6/β7 loops, differ greatly among the PH domains, and, in the case of the PLC-δ1PH, 
the β1/β2 and β3/β4 loops mainly interact with PtdIns(4,5)P2. Most PH domains are 
extremely electrostatically polarized (91). The calculated electrostatic potential 
around the β-spectrin PH domain revealed a defined region of positive potential 
centering on the β1/β2 loop, and a negative electrostatic potential surrounding the 
remainder of the protein. Such a characteristic of electrostatic sidedness is seen for 
all PH domains of known structure (92). 
 The majority of the PH domains interact with phosphoinositides with low affinity, 
with a Kd of greater than 10 μM, and display little to no specificity among 
phosphoinositides. However, several examples of specific interaction exist. For 
instance, the PLC-δ1 PH domain specifically recognizes PtdIns(4,5)P2 with high 
affinity (Kd of 1.7 μM) and localizes strongly to the plasma membrane (93;94). 
 The PH domains that bind specifically and with high affinity with the 
phosphoinositides display a simple motif of lysines and arginines in the β1/β2 loop 
sequence (95). In cases of PH domains with low-affinity binding of 
polyphosphoinositides, Lemmon et al. and Takeuchi et al. proposed that the weak 
interactions are a result of non-specific, or delocalized electrostatic attraction 
between an anionic ligand and the positively charged face of the electrostatically 
polarized protein domain (e.g. PH domains of pleckstrin and spectrin) (96;97). 
Specifically, Lemmon and colleagues in 2004 conducted a genome-wide analysis 
of all yeast PH domains for their ability to bind with high affinity and specificity to 
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phosphoinositides. Their results in a lipid overlay experiment surprisingly 
demonstrated that out of a total of 33 yeast PH domains, only one PH domain (from 
Num1p) specifically recognized PtdIns(4,5)P2; four exhibited preference for 
PtdIns(3)P; 22 promiscuously bound all phosphoinositides tested; and six showed no 
detectable binding (98). The authors further examined binding affinity of each yeast 
PH domain toward several physiological phosphoinositides using surface plasmon 
resonance (SPR). Results revealed only seven yeast PH domains exhibited high 
affinity binding to PtdIns(4,5)P2; the remaining produced a negligible SPR signal 
suggesting low affinity binding with Kd at high μM range. Homology models of the 
three-dimensional structures of all yeast PH domains were generated and illustrated 
positive electrostatic potential from β1/β2 and β5/β6 loops plays an important role in 
membrane targeting of these yeast PH domains. 
A “dual-key strategy” was proposed to be the mechanism of membrane targeting 
employed by numerous PH domains (99). That is, they bind another binding partner 
which specifically recognizes membrane lipids. As illustrated by Levine and Munro et 
al. (100), the PH domain of human oxysterol-binding protein (OSBP) simultaneously 
binds a small GTPase, ARF, that is Golgi specific and specifically recognizes the pool 
of PtdIns(4)P at the Golgi to facilitate OSBP membrane localization. 
1.4.2.2 EF-hand Repeats 
The term “EF-hand” was introduced by R.H. Kretsinger (101) over 30 years ago 
for the Ca2+-binding variant of a helix-loop-helix motif discovered in the structure of a 
small Ca2+-binding protein isolated from carp muscle. This motif was then found in 
Ca2+-binding proteins such as troponin C, myosin light chains, and calmodulin, to 
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name a few. It plays a key role in many aspects of cellular function. Fundamentally, 
diverse cellular functions are triggered by the simple event of Ca2+ attracting six to 
seven oxygen atoms of the EF-hand. EF-hand repeats always occur in pair and this 
structure is maintained by hydrogen-bonding and hydrophobic interactions in the 
Ca2+-binding loop and helices. The Ca2+-bound form of the motif is further stabilized 
by the Ca2+-ligand interactions and hydrogen bonding between polar groups and 
tightly bound water molecules (102;103). 
1.4.2.3 Catalytic domain 
A characteristic fold of triosephosphate isomerase (TIM) barrels consists of eight 
parallel β-strands on the inside, covered by eight α-helices on the outside (104). In a 
closed β-barrel a complete ring of hydrogen bonds is formed so that each β-strand is 
hydrogen-bonded with two neighboring strands. The TIM-barrel fold is found in 15 
distinct enzyme families and is the most common enzyme fold in the Protein Data 
Bank (PDB) database of known protein structures. Many enzymes containing TIM 
barrels catalyze completely unrelated reactions (105).  
In phospholipase C enzymes, the catalytic TIM barrel catalyzes the hydrolysis of 
PtdIns(4,5)P2. Specificity is conferred through key residues within the TIM-barrel of a 
PLC (discussion with greater details is provided in section 1.4.3). Two catalytic 
histidine residues mediate nucleophilic attack and subsequent hydrolysis on the 
substrate molecule and therefore are crucial to the PLC activity. A calcium ion is 
located at the active site, together with the two conserved histidine residues, directly 
participates in catalysis, consistent with the fact that all eukaryotic PLC isozymes 
require Ca2+ for their activities. Other key residues (Arg, Glu, Asn, Asp and Lys) within 
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the active site make contacts with calcium ion, phosphoryl group, hydroxyl group and 
the inositol ring via hydrogen bonds or van der Waals interaction. 
1.4.2.4 C2 domain 
C2 domains comprise approximately 120 amino acids, and they are membrane 
targeting modules found in many cellular signaling molecules. Often, their function 
depends on the presence of Ca2+ ions to mediate Ca2+-dependent localization of 
cellular proteins to the phospholipid containing plasma membrane (106). Lomasney 
et al. observed that PLC-δ1 bound to phosphatidylserine/phosphatidylcholine (PS/PC) 
vesicles in a concentration-dependent and saturable manner in the presence of Ca2+ 
(107). PS remarkably stimulated the rate of hydrolysis of PLC-δ1 by increasing the 
affinity of the enzyme for substrate vesicles. Removal of eight amino acid residues in 
the C2 domain impaired Ca2+-binding of PLC-δ1 and consequently reduced binding of 
PLC-δ1 with, and activation by, PS. An independent study also demonstrated the C2 
domains of PLC-δ1, -δ3, and -δ4 bind membranes in vitro using SPR and played a 
major role in subcellular localization of PLC-δ isozymes (108). 
Clark et al. showed in 1991 the presence of a C2-like domain in the amino 
terminus of cytosolic phospholipase A2 (cPLA2) that mediates Ca2+-dependent 
membrane translocation of cPLA2 (109). An amino terminal fragment of cPLA2, 
containing the C2 domain alone associated with membrane vesicles in a 
Ca2+-dependent manner. Perisic et al. and Evans et al. also observed cPLA2 
localization to ER, Golgi, or perinuclear membranes (PNM) via its C2 domain. Two 
calcium binding loops of the C2 domain penetrate into the phospholipid bilayer and 
dock the enzyme to the membrane to generate arachidonic acid. A key residue (D43) 
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in the C2 domain that binds calcium and surrounding hydrophobic residues, and its 
mutation result in drastically decreased phospholipid binding of cPLA2 (110). 
1.4.3 PLC-δ Subfamily 
PLC-δ isozymes are broadly distributed, but their mechanism of regulation 
remains unclear (77). PLC-δ is the second most sensitive to Ca2+ of all PLC isozymes 
(PLC-ζ is the most sensitive to Ca2+). Upon calcium binding with the EF-hand domain 
and the C2 domain, the PH domain of PLC-δ associates with its substrate 
PtdIns(4,5)P2 and its C2 domain forms a ternary complex with both 
phosphatidylserine and Ca2+ (107;111). It is hypothesized that increases in 
intracellular calcium concentration will trigger activation of this isozyme, which would 
place PLC-δ downstream of activation of other PLC isoforms. In PC12 cells, Kim et al. 
reported PLC-δ1 activation by capacitative Ca2+ entry in response to bradykinin 
activation of PLC-β (112).  
A high resolution structural model of the rat PLC-δ1 PH domain forming a 
complex with Ins(1,4,5)P3 has been determined by x-ray diffraction study at 1.9-Å 
resolution (113;114). The structure consists of a seven-stranded β sandwich formed 
by two orthogonal anti-parallel β-sheets and a C-terminal amphipathic α-helix. The 
amino acids that interact with Ins(1,4,5)P3 are mostly in the β1/β2 and β3/β4 loops of 
PLC-δ1PH. Direct hydrogen bonds are seen between the ligand Ins(1,4,5)P3 and 
seven amino acids. Two lysines, K30 and K57, directly make contacts with the 4- and 
5-phosphate groups of Ins(1,4,5)P3 in the binding pocket; R40, S55, R56 and E54 
completely bury the 5-phosphate of Ins(1,4,5)P3; and K30, K32, K57 and T107 
directly hydrogen bond with the 4-phosphate of Ins(1,4,5)P3.  
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Lomasney et al. reported that the PH domain of human PLC-δ1 regulates its 
enzyme activity (115). PtdIns(4,5)P2 specifically stimulated hydrolysis of 
phosphatidylinositol in a concentration-dependent manner, and this stimulation was 
inhibited by Ins(1,4,5)P3 in a concentration-dependent manner. However, N terminal 
deletion mutants of PLC-δ1 lacking the PH domain still catalyzed PI hydrolysis, but 
lost PtdIns(4,5)P2-dependent stimulation. Residues K24, K30, K32, R38 and W36 of 
the PH domain were shown to be responsible for the above observed phenomenon. 
Therefore, the PH domain of PLC-δ1 functions to modulate its enzyme activity, and 
PtdIns(4,5)P2 was identified as a functional ligand for this domain. These studies 
have demonstrated that PLC-δ1 isozyme senses the local concentration of its 
substrate PtdIns(4,5)P2 and is stimulated by its substrate. The product of this 
enzymatic reaction Ins(1,4,5)P3 competitively binds PLC-δ1 to form a negative 
feedback loop to terminate further PLC-δ1 hydrolysis activity. Binding to the inositol 
phosphate head group within the N terminal half of PLC-δ1PH is necessary but not 
sufficient for membrane localization of PLC-δ1. Using mutagenesis and chimeric 
studies, Varnai et al. also identified the C-terminal α-helix and the short loop between 
the β6/β7 sheets as critical components for membrane localization (116).  
A three-dimensional crystal structure of rat PLC-δ1 lacking its PH domain was 
solved with 2.4-Å resolution (117) (see Figure 1.7a). Four consecutive EF-hand 
repeats were revealed with their characteristic helix-loop-helix topology, and these 
are pair-wise distributed in two lobes. Only the loop regions of EF-hands 1 and 2 
contain calcium. However, no experimental evidence exists for a regulatory role for 
calcium-binding in the first lobe. The catalytic domain contains regions of highest 
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sequence similarity among all mammalian phospholipases. The crystal structure 
revealed a topology that resembles that of a TIM-barrel with a (βα)4β(βα)3 
architecture. The X-region of PLC-δ1 forms half of the barrel and the Y-region forms 
the other half. The active site locates on the C-terminal end of the eight-stranded 
β-barrel with dimensions of 18×13 Å at its outer rim and a maximal depth of 10 Å 
(Figure 1.7b). A 6-coordinated calcium ion is located at the bottom of the active site, 
making contacts with highly conserved residues Asn 312, Glu 341, Asp343, and Glu 
390. Mutation of Glu 341 to Gly destroys enzymatic activity of human PLC-δ1. 
Calcium also interacts with the axial 2-hydroxyl group of Ins(1,4,5)P3, and a 
2-deoxy-PtdIns was found to be non-hydrolyzable and binds weakly to mammalian 
PLCs. The aromatic ring of residue Tyr 551 lies parallel with the sugar ring of 
Ins(1,4,5)P3 and forms numerous van der Waals interactions. Two catalytic residues, 
His 311 and His 356, project their side chains into the active-site and form hydrogen 
bonds with the 1-phosphoryl group of Ins(1,4,5)P3. The equatorial 3-hydroxyl group of 
InsP3 engages interactions with Glu 341 and Arg 549 at the bottom of the active site 
through hydrogen bonds. There is insufficient space for phosphoinositides 
phosphorylated at this 3-hydroxyl group, and therefore, 3-phosphoinositides are not 
substrates for mammalian PLCs. The 4-phosphoryl group forms salt bridges with 
both the guanidinium group of Arg 549 and the amine group of Lys 438. Mutations of 
both residues completely abolish the hydrolysis of PtdIns(4,5)P2 (118;119), and these 
interactions are responsible for the observed substrate preference of PtdInsP2 > 
PtdInsP >> PtdIns. It was proposed that the PH domain of PLC-δ tethers the enzyme 
to the plasma membrane through specific binding to lipids, and the C2 domain fixes 
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the catalytic domain in a productive orientation to the membrane. 
The chemical reaction of phosphoinositide hydrolysis occurs in two steps with a 
nucleophilic attack of the axial 2-hydroxyl group of PtdIns(4,5)P2 followed by 
hydrolysis involving general base – general acid catalysis (117;120). According to the 
proposed mechanism, His 311 deprotonates the 2-OH group on inositol ring and His 
356 donates a proton to the leaving group O3 oxygen of diacylglycerol in the first step 
to generate myo-inositol 1,2-cyclic phosphate (IcP) (Figure 1.7c). Particulaly the Ca2+ 
ion was proposed in this step to lower the pKa of the 2-OH group and stabilizes the 
highly negatively charged transition state. In the second step, hydrolysis occurs and 
converts the cyclic IcP to acyclic myo-inositol 1-phosphate (IP). His 356 in this 
second step serves as a general base to activate a water molecule to facilitate the 
nucleophilic attack on the phosphate; whereas His 311 serves as a general acid that 
protonates the inositol O2 oxygen to facilitate the ring opening (Figure 1.7c). 
Therefore, PLC-catalyzed phosphatidylinositol hydrolysis constitutes of two steps, 
fast cleavage of phosphaticylinositol to DAG and cyclic inositol phosphate, and slow 
hydrolysis of cyclic inositol phosphate to acyclic inositol phosphate.  
1.4.4 PLC-γ Subfamily 
PLC-γ isozymes contain two SH2 (Src homology 2) domains and an SH3 (Src 
homology 3) domain as well as a split PH domain in the X-Y linker region, and are 
regulated by tyrosine kinase receptors and non-receptor tyrosine kinases 
(77;121-123). Binding of growth factors to their cognate receptors promotes 
dimerization of receptor subunits and stimulates receptor autophosphorylation on 
specific tyrosine residues. These phosphorylated residues serve as a docking site for 
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the SH2 domain of PLC-γ. Upon binding with the receptor, human PLC-γ1 is 
phosphorylated at conserved tyrosine residues, Tyr771, Tyr783, and Tyr1254 (124). 
Mutation of Tyr783 to Phe abrogated PDGF-mediated PLC-γ activation, although the 
mutant PLC-γ1 was still capable of association with the PDGF receptor (125). 
Localization of PLC-γ via its SH2 domain to the membrane and the interaction with, 
and phosphorylation by, the receptor promotes the targeting of PLC-γ1 to its lipid 
substrate, PtdIns(4,5)P2, in the membrane. In addition, membrane association of 
PLC-γ1 is also mediated through the interaction of the PH and the second SH2 
domains of PLC-γ1 with the PtdIns(3,4,5)P3 lipid molecules produced in response to 
growth factor stimulation (126-128). Members of non-receptor PTKs, such as Src, 
Syk and Tec, can also interact with and phosphorylate PLC-γ and therefore promote 
PLC-γ activation. In a similar mechanism, non-receptor PTKs are phosphorylated by 
cell surface receptors, such as T cell antigen receptor, B cell antigen receptor and the 
IgG receptor, on tyrosine residues, and therefore provide the docking site for SH2 
domain-containing PLC-γ to propagate signals from activated receptors (129). 
Alternatively, GPCRs can induce tyrosine phosphorylation of receptor PTKs such as 
those for PDGF, EGF, and insulin-like growth factor I (130) and non-receptor PTKs 
such as c-Src (131-134). Various lipid-derived molecules, such as PA and AA, also 
stimulate PLC-γ activity independent of PLC-γ phosphorylation (135-137), which 
would place PLC-γ downstream of PLD or PLA2 signaling. 
Rac GTPases recently were shown to stimulate the lipase activity of PLC-γ2 but 
not PLC-γ1 (138) by a mechanism involving translocation of the cytosolic PLC-γ2 to 
membranes independent of protein tyrosine phosphorylation and PtdIns(3,4,5)P3. 
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Since PLC-γ2 mediates numerous cellular responses in B-cells and Rac2 knockout 
mice displayed defects in cellular functions of hematopoietic stem cells, neutrophils, 
mast cells, T cells, and B lymphocytes, it was hypothesized that Rac GTPases may 
coordinate B-cell receptor-mediated PLC-γ2 activation (139) with integrins to allow B 
cells to recognize antigens at low concentrations. 
1.4.5 PLC-β Subfamily 
The PLC-β subfamily of PLC isozymes has been extensively studied over the 
past two decades. There are four mammalian PLC-β isozymes (β1,2,3,4) and they 
differ in their tissue distribution and in their ability to be regulated by G proteins (77). 
PLC-β1 and PLC-β3 are widely expressed. PLC-β2 is expressed primarily in 
hematopoietic cells and apparently is important for agonist-stimulated chemotaxis. 
PLC-β4 expression is found in retina and certain neuronal cells. G protein-coupled 
receptors that activate the Gαq-PLC-β signaling pathway include those for 
thromboxane A2, bradykinin, angiotensin II, histamine, vasopressin, acetylcholine, 
α1-adrenergic agonists, thyroid-stimulating hormone, chemokines, and endothelin-1.  
PLC-β isozymes are elaborated with a helical C-terminus (140), and are activated 
directly by Gα subunits of the Gq family of heterotrimeric G-proteins (141-143). Gβγ 
dimers released from heterotrimeric G-proteins of the Gi family also activate PLC-β2 
and PLC-β3 (23;144;145). Extensive studies recently have shown Rac activation of 
PLC-β2 (146;147). A crystal structure of Rac in complex with PLC-β2 has provided 
valuable insights in molecular interaction and mechanism of regulation of PLC-β 
isozymes (148).  
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In the early 1990s, the pertussis toxin-insensitive Gα subunits of the G protein 
Gαq demonstrated marked AlF4--dependent stimulation of the phospholipase activity 
of PI-PLC partially purified from bovine brain (141). Taylor et al. provided further 
evidence that activated Gαq or Gα11 specifically activates PLC-β but not PLC-δ or 
PLC-γ (142). Moreover, Waldo et al. reported that by combining a 150 kDa PLC 
purified from turkey erythrocyte (PLC-βt (149;150)) with the cholate extract of the 
turkey erythrocyte plasma membrane in the substrate containing phospholipid 
vesicles, the PLC lipase activity was potentiated in the presence of AlF4- (143). This 
observation suggested an AlF4--activated G protein present in the turkey erythrocyte 
membrane that activates PLC-βt (homologue of mammalian PLC-β2). The G protein 
conferring regulation to PLC-βt was purified to homogeneity utilizing reconstitution of 
AlF4--sensitivity as an assay. The purified protein was reactive to antibody raised 
against Gαq/11. Smrcka et al. in 1993, illustrated all three subtypes of PLC-β (PLC-β1, 
-β2, and -β3) were activated by purified Gαq/11 with the following relative efficacies: 
PLC-β3 ≥ PLC-β1 > PLC-β2 (151). This observation was confirmed by Jhon et al. and 
these authors further examined three α subunits of the Gq class G proteins, Gαq, 
Gα11, and Gα16 and found that all three α subunits activated all three subtypes of 
PLC-β (152). Kozasa et al. in the same year independently demonstrated Gα16, 
which is expressed only in hematopoietic cells and is distantly related to Gαq, 
activated PLC-β1, -β2, and -β3 in an essentially same manner as Gαq (153).  
The C terminal tail portion of the PLC-β isozymes contains three α-helical regions 
with highly conserved basic residues. Studies with deletion constructs of PLC-β 
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lacking the C terminal region beyond the C2 domain suggested that this C terminal 
region is required for specific binding of and stimulation by Gαq (154). Kim CG et al. 
further identified clusters of basic residues in two helical regions of PLC-β1 C tail, that 
when mutated, greatly reduced the extent of activation by Gαq and association with 
the particulate fraction (155). In 2002, Singer and colleagues solved the crystal 
structure of the C terminal sequences of PLC-βt and revealed three helices to form a 
coiled coil that dimerizes in an antiparallel orientation (140). A homology-modeled 
structure of Gαq docked to the dimeric structure of PLC-βt C tail consistently revealed 
regions for Gαq interaction implicated in mutagenesis studies. Interestingly, Wang et 
al. reported that the C2 domains of PLC-β1 and PLC-β2 associate with activated Gαq 
(GTPγS bound), but not the plasma membrane; and that the C2 domain binds only to 
the activated Gαq, but not Gαq·GDP (156). The C2 domain of PLC-δ (not regulated by 
Gαq) does not associate with Gαq. Whether or not the C2 domain of PLC-β1 and 
PLC-β2 serves as a surface to facilitate Gαq activation of native PLC-β proteins will 
require further examination, and a crystal structure containing both the C2 domain 
and the C tail in complex with Gαq would provide more insight into the involvement of 
C2 domain in Gαq-mediated PLC-β activation. 
Berstein et al. observed that PLC-β1 markedly stimulated hydrolysis of 
Gαq/11·GTP and acts as a GTPase-activating protein (GAP) for its physiologic 
regulator, Gαq/11 (6). Paulssen et al., using C terminal fragments of PLC-β1 with 
varying sizes, demonstrated the GAP activity for Gαq resides within the C-tail of 
PLC-β1 (157). Ilkaeva et al. in 2002 further identified residues in the C tail helical 
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region that selectively regulate responsiveness to Gαq stimulation versus the GAP 
activity toward Gαq (158). However, most mutations within the C tail affected both the 
responsiveness to Gαq stimulation and the GAP activity of PLC-β1, and these 
mutations were mapped to the dimer interface implicated in the crystal structure by 
Singer et al. (140).  
PLC-β1 also was found to be a major PLC isoform in the cell nucleus and the C 
terminal region of the protein is required for nuclear localization. This isozyme is 
required for the onset of DNA synthesis in response to insulin-like growth factor I 
(159).  
Gβγ dimers of the heterotrimeric G proteins were discovered in the early 1990s to 
regulate PLC-β isozymes (23;145;151;160). PLC-β2 is the most sensitive to Gβγ 
stimulation, while PLC-β1 is the least sensitive. Gβγ exhibits high affinity binding for 
PLC isozymes in the following rank order: PLC-β2 ≥ PLC-β3 >> PLC-β1. The 
activation of PLC-β2 by Gβγ in response to numerous cell surface receptors has been 
demonstrated in transfected COS cells (78). It is believed that it is the free Gβγ 
released from the pertussis toxin-insensitive Gα subunits of Gi proteins upon receptor 
activation that predominantly mediate PLC-β2 activation. The concentrations of Gβγ 
needed to maximally activate PLC-β isoforms in vitro are much higher than the 
effective concentrations of Gαq. However, the maximal extent of activation by the two 
regulators is similar. Boyer et al. specifically observed inhibition of AlF4--induced 
activation of PLC when reconstituting purified turkey erythrocyte or bovine brain 
βγ-subunit into phospholipid vesicles; however at higher concentrations, βγ-subunit 
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markedly stimulated PLC activity (23). Thus, both Gαq and Gβγ contribute to the 
activation of PLC-β in cells. In platelets, however, Gαq appears to be the essential 
activator of PLC-β, and this activation cannot be replaced by Gβγ (161). Platelets 
derived from Gαq-deficient mice are unresponsive to a variety of physiological platelet 
activators, such as ADP, thrombin, U46619 (TxA2 receptor agonist), and collagen.  
Several combinations of different Gβ and Gγ subunits also activate PLC-β 
isozymes (162). The authors tested five different Gβγ complexes of defined 
composition, rat Gβ1γ2, rat Gβ1γ3, rat Gβ2γ2, rat Gβ2γ3,, bovine brain Gβγ, and turkey 
erythrocyte Gβγ, in their ability to stimulate PLC-βt and discovered four of the Gβγ 
complexes activated PLC with similar activities while Gβ2γ3 was less effective. This 
result suggests that other Gβγ complexes with distinct compositions that have not 
been tested might have even larger differences in their activation of PLC-β isozymes 
and potentially other subtypes of PLC isozymes. 
The fact that additive stimulation of PLC-β3 by both Gβγ and Gαq/11 was observed 
suggests separate sites for interaction of PLC with G protein subunits, and this 
interaction differs depending on the enzyme subtypes and the concentration of Mg2+ 
(151). Studies have shown that Gβγ dimer interacts with multiple sites in PLC-β 
isozyme. The sites of interaction of PLC-β2 with Gβγ were mapped to 62 amino acid 
sequences (residues Leu580 to Val641) of PLC-β2 by testing GST fusion proteins 
comprising various PLC-β2 fragments in the in vitro binding assay (163). Sankaran et 
al. has narrowed down the interaction sites to the 20 amino acid sequences in the Y 
domain using peptide studies (164). In 1999 Wang et al. reported that membrane 
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associated Gβγ also bound to the isolated PH domain of PLC-β2 using fluorescence 
resonance energy transfer (FRET) (165). Furthermore, the isolated PH domain of 
PLC-β2 or PLC-β1 has similar affinity for Gβγ, but is much greater than that of PLC-δ1. 
In addition, a chimera comprised of the PH domain from PLC-β2 and the rest of 
PLC-δ1 were responsive to Gβγ regulation similar to that of wild type PLC-β2 (166). 
These findings have suggested PH domain functions more than a membrane 
targeting motif but rather to facilitate regulatory signals to the host protein.  
A study by Gierschik and coworkers identified PLC-β2 as a novel effector of Rac1 
and Cdc42 in a GTPγS-dependent manner in neutrophils (167). This study illustrated 
the first mammalian effector directly regulated by both the heterotrimeric G proteins 
and the Ras superfamily of small GTPases. Snyder et al. screened 17 Rho GTPases 
for their ability to directly bind and activate purified PLC-β isozymes (147). Rac1, 
Rac2, and Rac3 were the only Rho GTPases that stimulated PLC-β activity in vivo, 
and directly bound PLC-β2 and PLC-β3 as quantified using SPR. Moreover, the 
authors demonstrated that the PH domain of PLC-β2 is the putative effector site for 
Rac GTPases, which defined a novel role for this PH domain. Illenberger et al. 
attempted to delineate the structural elements of PLC-β2 regulation by both Gβγ and 
Rac2 using chimeras of PLC-β2 and PLC-β1 and demonstrated that the catalytic 
domain of PLC-β2 is necessary and sufficient for Gβγ stimulation (146). Although the 
PH domain is absolutely required for Rac2 activation of PLC-β2, the PH domain of 
PLC-β2 enhances Gβγ activation of PLC-β2. 
The three-dimensional crystal structure of Rac1 bound to its effector PLC-β2 
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revealed a planar triangular geometry at 2.2-Å resolution with the GTPase, the 
catalytic TIM barrel and the EF-hand domain of PLC-β2 as the three vertices of the 
triangle (148). The interaction between the two proteins occurs entirely and 
exclusively through the switch regions of Rac1 and the PH domain of PLC-β2, 
consistent with previous biochemical studies (147). The authors also have identified 
five key amino acids (Ile24, Pro35, Arg22, Gln52 and Tyr118) within the PH domain 
that are responsible for binding Rac, with Gln52 being the most pivotal residue. 
Mutation of Gln52 to alanine remarkably reduced Rac1 activation of PLC-β2, but did 
not affect Gβγ activation of the enzyme. In addition, Rac1 binding to PLC-β2 did not 
propagate conformational changes within the active site. This unique molecular 
insight will help dissect the distinct signaling pathways that converge at PLC-β2. The 
PH domain of PLC-β2 also interacts extensively with the catalytic TIM barrel, and it 
was hypothesized by the authors that the PH domain, through binding with Rac1, not 
only localizes the enzyme to the membrane, but more importantly orients the enzyme 
to position the catalytic TIM barrel to its phosphoinositide substrate at the membrane 
surface. It was also observed from the crystal structure of PLC-β2 in complex with 
Rac1 and a holo-PLC-β2 crystal structure (Hicks et al., unpublished) that the active 
site in PLC-β2 was occluded by a loop in the X-Y linker region. These studies strongly 
suggest that the active site-occluding X-Y-linker moves as a consequence of dense 
negative charges in the linker encountering negatively charged membrane surfaces; 
autoinhibition is therefore relieved and access to PtdIns(4,5)P2 substrate is promoted.  
The PLC-β isozymes contain a putative (S/T)-X-(V/L) PDZ binding motif at their 
C-termini. Hwang et al. used yeast two hybrid screening and identified NHERF2 
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(Na+/K+ exchanger regulatory factor 2) as a binding partner of PLC-β3 via C-terminal 
NTQL sequences of PLC-β3 and the second PDZ domain of NHERF2 (168). The 
authors further demonstrated using immunoprecipitation assay that NHERF2 only 
interacted with PLC-β3, but not with other PLC-β isoforms. Furthermore, they 
observed in both COS-7 and HeLa cells that NHERF2 potentiates PLC-β activation 
by carbachol. In the same year, an independent group reported somewhat conflicting 
results. That is, both bovine PLC-β1 and PLC-β2 interacted with the first PDZ domain 
of NHERF using immunoprecipitation in both HEK293 cells and in adult mouse brain 
(169). Mahon et al. demonstrated NHERF2 simultaneously binds PLC-β1 and PTH1R 
(parathyroid hormone 1 receptor) through PDZ1 and PDZ2 domains, respectively 
(170). When PS120 cells (the Chinese hamster fibroblast) expressing 
PTH1R-NHERF2 complexes were treated with PTH (parathyroid hormone), PLC-β 
was markedly activated and adenylyl cyclase inhibited. Oh et al. reported that 
NHERF2, using the second PDZ domain, indirectly links LPA2 receptors and PLC-β3 
to form a complex (171). The authors believe NHERF2 potentiates LPA-induced ERK 
activation and subsequent cyclooxygenase-2 induction via a PLC-dependent 
pathway. Whether NHERF can interact with only one isoform of PLC-β or this 
NHERF/PLC-β interaction is cell type specific will need further experimentation to 
resolve. Whether NHERF cooperates in the signaling pathway from the cell surface 
receptor to PLC-β, and even signal propagation to downstream signaling components 
will need careful examination. 
1.4.6 PLC-ε Subfamily 
To search for effector proteins of LET-60 (homologue of mammalian Ras) in the 
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nematode Caenorhabditis elegans, Kataoka and colleagues employed 
yeast-two-hybrid screening for LET-60-binding proteins. Shibatohge et al. in 1998 
identified a novel protein containing two tandem RA domains at the carboxyl terminus 
and a CDC25 Ras-GEF domain at its amino terminus (172). Surprisingly, the authors 
discovered that their newly identified Ras effector contained regions highly 
homologous to the PI-PLC family proteins (the catalytic X and Y domain and the C2 
domain) with an apparent molecular mass of 210 kDa. Moreover, this Ras effector 
exhibited hydrolyzing activity toward PtdIns(4,5)P2 in the presence of 10 μM calcium. 
Therefore, this novel C. elegans PI-PLC was designated as PLC210.  
This discovery in C. elegans triggered three independent laboratories to search 
for mammalian homologues of PLC210 and identify a single gene encoding a protein 
with an N terminal CDC25 Ras-GEF domain, PH domain, four EF-hand repeats, 
catalytic X and Y box, C2 domain, and C terminal tandem RA domains, designated as 
PLC-ε (173-175). They demonstrated a widely expressed novel PLC isozyme and 
illustrated that constitutively active H-Ras specifically associated with PLC-ε and 
promoted its membrane localization and activation. Gα12 (174) and Gα13 (176) also 
activated PLC-ε in transfected cells, and the activation of MAPK pathways was 
increased in a PLC-ε-dependent manner (174). 
Subsequently, Gβγ subunits of the heterotrimeric G proteins were shown to 
stimulate PLC-ε lipase activity in transfected COS-7 cells (176). However, 
reconstitution of the purified Gβγ in phospholipid vesicle system failed to promote 
PLC-ε activation ((173) and Seifert et al., unpublished), suggesting an indirect 
mechanism of regulation of PLC-ε by Gβγ in cells.  
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Further characterization of the Gα12/13?PLC-ε activation pathway identified Rho 
GTPases which directly activate PLC-ε and signal downstream of Gα12/13 (81). The 
authors observed marked stimulation of PLC-ε when RhoA, RhoB, or RhoC was 
co-transfected with PLC-ε in COS-7 cells, but not when other Rho family members 
(i.e. Rac1, Rac2, Rac3, and Cdc42) were examined. This activation exceeded that 
caused by all other known regulators (Gα12/13, Gβγ, and Ras) of PLC-ε. Furthermore, 
truncation mutants of PLC-ε lacking the C terminal tandem RA domains lost 
responsiveness to Ras but not to Rho, illustrating that the activation of PLC-ε by Rho 
GTPases occurred independently of Ras. Wing et al. also revealed a 65 amino acid 
sequence insert in the Y domain (Y insert) of PLC-ε of all species that is not present 
in PLC-β, -δ, -γ, -ζ, and -η. Truncation of this 65-amino acid stretch caused PLC-ε to 
be no longer activated by Rho and Gα12/13, but activation by Ras or Gβγ was retained 
(81). In addition, GTP-dependent activation of purified PLC-ε by purified Rho was 
illustrated in vitro by Seifert et al., and purified PLC-ε lacking the Y insert also was no 
longer activated by Rho (177). Therefore, Rho and Ras family of small GTPases 
activate PLC-ε at distinct sites and by distinct mechanisms. 
The identification of the CDC25 GEF domain at the N terminus of PLC-ε has 
provoked several laboratories to determine the downstream effectors of this intriguing 
domain. Contradictory results have been published, demonstrating PLC-ε as an 
exchange factor for Ras or Rap1 (174;178). The GEF activity of PLC-ε apparently is 
independent of its PtdIns(4,5)P2 hydrolysis. Ras and Rap1 have been reported to 
play an important and cooperative role in the regulation of PLC-ε-mediated cell 
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survival and growth (179).  
It was also shown that Gαs-coupled receptors, such as the β2-adrenergic receptor 
(β2-AR) in HEK-293 cells, or the prostaglandin E1 receptor (PGE1 R) in NIE-115 
neuroblastoma cells, can potentially activate PLC-ε through formation of cAMP which 
in turn activates the GEF for Rap GTPases, Epac1, resulting in subsequent activation 
of Ras-related GTPase Rap2B (180). The downstream effector of cAMP, protein 
kinase A (PKA), was not involved. Furthermore, Evellin et al. showed that M3 
muscarinic acetylcholine receptor (M3 mAchR) stimulated both PLC-β1 via Gαq and 
PLC-ε via Gαs-dependent cAMP formation and subsequent Rap2B activation (181). 
The PLC-ε gene is located on chromosome 10 (10q23.33) and there exist two 
mRNA splice variants, PLC-ε1a and PLC-ε1b. The splicing event occurs at the N 
terminus where the splice variants employ a distinct first exon (182). PLC-ε1a is 
expressed widely in normal tissues, and PLC-ε1a is the predominant form present in 
most cell lines. PLC-ε1b expression is more restricted and absent from a variety of 
cell lines. However, PLC-ε1a expression is found to be greatly reduced in tumor 
tissues due to epigenetic silencing through hypermethylation (182). Thus, Katan and 
colleagues have discovered another level of regulation of PLC-ε in tumor cells. 
Analysis of PLC-ε expression by in situ hybridization and immunohistochemistry 
revealed that neural precursor cells committed to the neuronal lineage induce PLC-ε 
expression, and this expression persists in the terminally differentiated neurons 
(183).  
Katan and colleagues have solved an NMR structure of PLC-ε RA domains (RA1 
and RA2) and a crystal structure of RA2 in complex with Ras (184). Their structures 
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have demonstrated a role for RA2 domain to target PLC-ε to membranes, and they 
propose that the RA2 domain facilitates intramolecular inhibition in the resting state of 
PLC-ε. 
1.4.7 PLC-ζ Subfamily 
All PLC isozymes contain canonical PH, EF-hand repeats, catalytic TIM barrel 
and C2 domains, with the exception of sperm-specific PLC-ζ, which lacks a PH 
domain. This isozyme was first cloned in 2002 by Saunders et al. (accession number: 
P10688) and characterized as a 74 kDa protein, being the smallest among all PLC 
isoforms (185). Their results unambiguously illustrated the sperm PLC-ζ as the 
physiological trigger of egg activation, and thus, this PLC isozyme is an essential 
protein for mammalian fertilization and embryo development.  
The catalytic domain of PLC-ζ contains the conserved residues in the active site 
of PLC-δ1 corresponding to Histidine 178, Aspartate 210 and Histidine 223. The 
extended X-Y linker sequences in PLC-ζ contain a high proportion of charged 
residues. Clustal sequence alignment of PLC-ζ with other mammalian PLC isoforms 
illustrated the degree of similarity with the rank order of δ > γ > β > ε (185). The 
phylogenetic analysis of all mammalian PLCs suggests ζ is the least divergent PLC 
isoforms from a hypothetical precursor, with the rank order of ζ > δ > β > ε > γ (185). 
Abundant levels of mRNA transcripts and PLC-ζ protein were found only in 
mouse sperm tissues (185). Microinjection of eggs with PLC-ζ complementary RNA 
(cRNA) caused robust Ca2+ oscillations. Moreover, the frequency of Ca2+ oscillation, 
but not necessarily the amplitude, varied with PLC-ζ cRNA concentration, which 
directly coincided with the phenomenon observed with microinjection of different 
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concentrations of sperm extract. Depletion of PLC-ζ or expression of a mutant 
(Aspartate 343 to Arginine) that abolished its phospholipase activity abrogated Ca2+ 
oscillations.  
Nomikos et al. reported recently a cluster of basic residues in the X-Y linker 
region of PLC-ζ that acts as a motif for membrane anchoring (186). This 
phenomenon occurs with precedence, such as the unstructured clusters of basic 
residues found in Src and K-Ras facilitate the anchorage of proteins to membranes 
via electrostatic interactions with acidic lipids (187;188). 
1.5 Physiological Functions of Phospholipase C 
A study reported an importance of PLC-δ4 function in the zona pellucida-induced 
acrosome reaction (189). Inactivation of the PLC-δ4 gene by targeted disruption of 
exons 2-5 did not result in embryonic lethality. Although homozygous adult PLC-δ4(-/-) 
mice had no obvious abnormalities in the brain, liver, kidney, or heart, PLC-δ4(-/-) 
male mice were infertile. All eggs failed to incorporate sperm when inseminated with 
PLC-δ4(-/-) sperm, suggesting an essential role of PLC-δ4 protein during early events 
leading to sperm fusion in mammalian fertilization. The authors accessed other PLC 
isoforms present in sperm, testis, and epididymis, and found expression of PLC-β1, 
-β3, -γ2, and -δ2 and that their expression was not modified by the loss of PLC-δ4 
protein. This result suggested a specific function of PLC-δ4 or maybe a particular 
pathway involving only PLC-δ4 because the presence of multiple PLC isoforms 
cannot compensate for PLC-δ4. However, it is noteworthy that this report was before 
the identification of PLC-ζ, and it will be useful to further examine now whether PLC-ζ 
could be involved in acrosome reaction. 
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PLC-β1 is highly expressed in cerebral cortex and hippocampus, and PLC-β4 
expression is found in retina and certain neuronal cells. PLC-β1(-/-) mice developed 
epilepsy and PLC-β4(-/-) mice showed ataxia (190). PLC-β1 primarily couples to the 
muscarinic acetylcholine receptor in the brain, whereas PLC-β4 couples to 
metabotropic glutamate receptors. PLC-β1 also plays an important role in the 
checkpoint of the cell cycle. An interstitial deletion of the PLC-β1 gene at 
chromosome 20p12 can occur in patients with myelodysplastic syndrome (MDS), an 
adult hematological disease. MDS patients who bear this PLC-β1 gene deletion will 
rapidly evolve into acute myeloid leukemia (AML) (191). 
Xie et al. tried to establish a link between PLC-β3 and morphine and μ 
opioid-mediated responses using PLC-β3 null mice (192). A specific μ opioid receptor 
agonist, DAMGO ([D-Ala2,(Me)Phe4,Gly(ol)5] enkephalin), signaling through Gαi/o, 
induced increase in intracellular [Ca2+] in wild type animals, but not in PLC-β3(-/-) 
mice (the Gαq signaling pathway is still intact). A ten-fold increase in efficacy in 
response to morphine was observed in PLC-β3(-/-) when compared with wild type 
mice; and a greater reduction in whole-cell current was observed in PLC-β3(-/-) mice. 
This study demonstrated an increased cellular responses to μ agonists in PLC-β3(-/-) 
mice; however, the authors have not addressed the involvement of other PLC 
isoforms. To establish an unequivocal role of PLC-β3 in morphine mediated analgesia 
will require additional experiments to eliminate the possible involvement of other 
PLC-dependent pathways. 
Chemoattractants, such as N-formyl-Met-Leu-Phe (fMLP), interleukin-8 (IL-8), 
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and macrophage inflammatory protein (MIP)-1α, -induced Ins(1,4,5)P3 production 
and Ca2+ efflux were not detected in mouse neutrophils lacking PLC-β2 and/or 
PLC-β3 (193). PLC-β3(-/-) or PLC-β2(-/-)/PLC-β3(-/-) mice develop spontaneous 
multifocal skin ulcers due to hyperinfiltration of leukocytes in the lesion tissues 
(193;194). Clearly PLC-β2 and PLC-β3 play important roles in 
chemoattractant-induced responses. 
Embryonic lethality at embryonic day (E) 9.0 was observed when PLC-γ1 gene 
was disrupted (195). PLC-γ1(-/-) embryo appeared normal prior to E 8.5, but failed to 
continue normal development and growth, suggesting an essential role of PLC-γ1 
signaling required for normal development of the embryo that cannot be 
compensated by other tyrosine kinase signaling pathways or other PLC-mediated 
pathways. In contrast, PLC-γ2(-/-) mice are viable but develop numerous defects in B 
cell and platelet functions (196). 
Kataoka and coworkers examined the physiological outcome of mice whose 
PLC-ε was catalytically inactivated by gene targeting (197). The hearts of these 
homozygous mice develop congenital malformations of both the aortic and 
pulmonary valves causing severe regurgitation and ventricular dilation, suggesting a 
defect in valve remodeling at late stages of semilunar valvulogenesis. The authors 
believe that PLC-ε plays a crucial role downstream of EGFR signaling to regulate 
semilunar valvulogenesis. 
A second study illustrated that PLC-ε(-/-) mice exhibit late onset and reduced 
incidence of skin squamous tumors, providing strong evidence for PLC-ε being an 
important effector of Ras oncogenes in promotion of oncogenesis (198). Gene 
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deletion of PLC-ε in C. elegans resulted in delayed dilation of spermatheca-uterine 
valve, and therefore PLC-ε functions downstream of LET-23 (a C. elegans receptor 
tyrosine kinase) to regulate ovulation (199-201). Another study suggested that 
induction of PLC-ε expression is a specific event associated with the commitment of 
neuronal precursor cells to the neuronal lineage (183). Homozygous gene deletion of 
PLC-ε in mice resulted in higher susceptibility to hypertrophy in response to chronic 
cardiac stress (202).  
1.6 PLC-η Subfamily 
Our laboratory and three other research groups independently reported in 2005 
the identification of the newest subfamily PLC-η (82-85). The research described 
herein encompasses the cloning of a full-length form of human PLC-η2, the discovery 
of multiple splice variants of PLC-η2 in both human and mouse and their differential 
expression, and identification of one possible activator of PLC-η2 both in vivo and in 
vitro using purified enzymes in a model phospholipid vesicle system. This work is the 
subject of Chapter 2, 3, and 4 of this dissertation. 
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Figure 1.1. GPCR and Heterotrimeric G-Protein Signaling Cycle. 
G-protein-coupled receptors are seven-transmembrane-domain-containing cell 
surface macromolecules. In the absence of ligand, the Gα subunit is GDP-bound and 
tightly associates with the Gβγ subunit. Gβγ acts as a guanine nucleotide dissociation 
inhibitor for Gα·GDP, and slows the spontaneous exchange of GDP for GTP. 
Agonist-activated GPCR acts as a guanine nucleotide exchange factor (GEF), which 
induces conformational changes in the Gα subunit and allows Gα to exchange GDP 
for GTP. Gα·GTP dissociates from Gβγ dimer and each subunit is capable of 
signaling to downstream effectors. The Gα subunit has intrinsic GTPase activity to 
hydrolyze the γ-phosphate of GTP returning the activated subunit to the basal state 
and reassociating with Gβγ.  
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Figure 1.2. Crystal structure of Gαi1·GDP·Mg2+ (from reference (12)) and the 
nucleotide binding pocket in the crystal structure of Gαt·GDP·AlF4-·H2O (from 
reference (7)). 
(a) Crystal structure of Gαi1·GDP·Mg2+ complex in the presence of 200 mM Mg2+. The 
helical domain is colored light blue and the GTPase domain is colored dark blue. 
GDP (green), Mg2+ (cyan), and two SO42- (orange) are shown as ball-and-stick 
models. Switch I residues (disordered: 177-185; ordered: 200-203) are colored 
magenta. Most of switch II (residues 204-217) and switch III (residues 233-239) are 
disordered, and they are colored yellow. (b) The nucleotide binding pocket in the 
crystal structure of Gαt·GDP·AlF4-·H2O. All interactions between GDP·AlF4-·H2O and 
stabilizing residues involve highly conserved amino acids in the GTPase superfamily. 
The water molecule in the GDP·AlF4-·H2O complex maintains a strong hydrogen bond 
with the carbonyl of Thr 177. The side chain of Gln 200 forms two strong hydrogen 
bonds to AlF4-·H2O, one between the amide NH and a fluoride ion and another 
between the carbonyl oxygen and the water. The aluminum tetrafluoride is further 
stabilized by interactions of the fluorides with the guanidinium group of Arg 174, the 
amino group of Lys 42, and the backbone NH of Gly 199. 
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Figure 1.3. Crystal structures of transducin Gβγ (from reference (16)). 
(a) Crystal structure of transducin Gβγ in the ribbon drawing viewed down the central 
tunnel. The 7 WD-repeats are colored red, orange, yellow, dark green, blue, silver, 
and magenta. β-strands comprising one WD-repeat are labeled numerically from 1-4. 
Each WD-repeat (β-sheet) is labeled numerically with a prefix ‘s’. 
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Figure 1.4. The pathway of PLC activation and generation of two second 
messengers. Binding of an agonist to a GPCR at the cell surface activates the 
heterotrimeric G protein. Either activated Gα·GTP or Gβγ dimer activates PLC. PLC 
catalyzes the hydrolysis of the minor membrane lipid, PIP2, and generates IP3 and 
DAG. Water soluble IP3 binds to the IP3 receptor on ER membrane and triggers the 
release of Ca2+ sequestered in the ER which in turn activates numerous cellular 
processes. IP3 is then metabolized by inositol phosphatases to yield inositol. The 
nonpolar DAG remains membrane-associated and activates PKC to phosphorylate a 
number of cellular proteins, and thereby triggers cellular processes. Activation of PKC 
also requires Ca2+ and PS as cofactors. DAG is then metabolized by a diacylglycerol 
lipase to yield monoacylglycerol and arachidonic acid.  
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Figure 1.5. Domain structures of the mammalian PLC family members. 
The canonical domain structure of a PLC includes a pleckstrin homology domain 
(PH), four EF-hand repeats, catalytic TIM barrel (X and Y domain), and a C2 domain. 
Six PLC subfamilies are distinguished by unique domain motifs. PLC-β is elaborated 
with a helical C tail motif. PLC-γ contains a split PH domain and two SH2 domains 
and a SH3 domain in the X-Y linker region. PLC-ε contains an N-terminal CDC25 
(Ras GEF) domain and C-terminal tandem RA (Ras-associating) domains. Within the 
Y box of PLC-ε, there is an insert of 65 amino acids that is required for Rho activation 
(black bar). PLC-ζ lacks a PH domain, and PLC-η contains a C tail with a 
PDZ-binding motif at its C terminus. 
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Figure 1.6. Amino acid sequences alignment of all PLC isozymes.  
Amino acid sequences of sixteen PLC isozymes (encompassing all forms of PLC) are 
aligned using ClustalX (see alignment in Appendix). The results of above sequence 
alignment are illustrated by the phylogenetic tree. 
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Figure 1.7. Crystal structure of rat PLC-δ1 (lacking PH domain) and its catalytic 
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site in complex with IP3 (adopted from reference (117)). 
(a) Ribbon diagram representation of rat PLC-δ1. The N-terminal EF-hand repeats 
are colored in purple, the catalytic TIM barrel in yellow, and the C-terminal C2 domain 
in cyan. The C2 domain makes extensive contacts with both the EF and catalytic 
domains. The linker between EF-hand repeats and the catalytic domain is colored in 
red, and the linker between catalytic domain and C2 domain is colored in green. (b) 
Schematic diagram of the network of IP3 and Ca2+ interactions with important 
residues from both the X and Y domain at the active site. (c) Proposed reaction 
mechanism for PtdIns(4,5)P2 hydrolysis.  
CHAPTER 2 
MOLECULAR CLONING AND CHARACTERIZATION OF A NOVEL 
PHOSPHOLIPASE C ENZYME, HUMAN PHOSPHOLIPASE C ETA2 
(Portions of this chapter are previously published on Biochemical Journal 2005 Nov 
1;391(Pt3):667-76.) 
 
2.1 Abstract 
Phospholipase C (PLC) isozymes catalyze the conversion of 
phosphatidylinositol-(4,5)P2 to the Ca2+-mobilizing second messenger, Ins(1,4,5)P3, 
and the protein kinase C-activating second messenger, diacylglycerol.  With the goal 
of identifying additional mammalian PLC isozymes, we screened the NCBI 
non-redundant database using a BLAST algorithm for novel sequences with 
homology to the conserved PLC catalytic core.  Two unique sequences 
corresponding to two unknown PLC isozymes were identified, and one of these, 
designated PLC-η2, was cloned and characterized.  Most of the coding sequence of 
PLC-η2 was constructed from two ESTs, which included overlapping sequence that 
was confirmed by multiple ESTs and mRNAs.  5’-RACE also identified an upstream 
exon not deduced from available EST or mRNA sequences.  Sequence analysis of 
PLC-η2 revealed the canonical domains of a PLC isozyme with an additional long 
carboxyl terminus that contains a class II PDZ binding motif.  Genomic analyses 
indicated that PLC-η2 is encoded by 23 exons.  RT-PCR analyses illustrated 
expression of PLC-η2 in human retina and kidney as well as in mouse brain, eye, and 
lung.  RT-PCR with exon-specific primers also revealed tissue specific expression of 
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four splice variants in mouse that represent alternative use of sequence in exons 21, 
22, and 23.  PLC-η2-specific antisera recognized one of these splice variants as an 
approximately 155 kDa species when expressed in COS-7 cells; PLC-η2 natively 
expressed in 1321N1 human astrocytoma cells also migrated as an approximately 
155 kDa species.  Phospholipase C activity was observed in vitro and in vivo for 
three different constructs of PLC-η2 each containing possible alternatively spliced 
first exons.  Coexpression of PLC-η2 with Gβ1γ2 dimers of heterotrimeric G proteins 
resulted in marked stimulation of inositol lipid hydrolysis.  Thus, PLC-η2 may in part 
function downstream of G protein-coupled receptors.   
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2.2 Introduction 
Phospholipase C (PLC) catalyzes conversion of phosphatidylinositol-(4,5)P2 to 
the Ca2+-mobilizing second messenger, Ins(1,4,5)P3, and protein kinase C-activating 
second messenger, diacylglycerol (47;203).  Inositol lipids also specifically bind to 
conserved PH, FYVE, PX, and other domains (204;205), and therein play additionally 
important roles directly regulating membrane association and/or activity of a broad 
range of proteins.  By altering the ratio of membrane phosphoinositides, PLC 
isozymes potentially affect membrane association and activity of many signaling 
proteins.  Whereas the original conception of inositol lipid signaling focused on 
receptor-promoted regulation of PLC at the plasma membrane, inositol lipids regulate 
protein function at many subcellular locations (70;206;207), and the presence of PLC 
isozymes in most cellular compartments suggest diverse activities of these signaling 
proteins.   
Given the broad physiological roles played by phosphoinositides, it is not 
surprising that a large family of PLC isozymes exist (77).  All five classes of PLC 
(PLC-β, γ, δ, ζ and ε) contain canonical PH, EF hand, catalytic TIM barrel, and C2 
domains with the exception of sperm specific PLC-ζ (185), which lacks a PH domain.  
PLC-δ isozymes are broadly distributed, but their mechanism of regulation remains 
elusive (77).  PLC-γ isozymes contain SH2 and SH3 domains and are regulated by 
tyrosine phosphorylation by tyrosine kinase receptors and non-receptor tyrosine 
kinases (77;121-123;208).  PLC-β isozymes are elaborated with a helical carboxyl 
terminus (140) and are activated directly by Gα subunits of the Gq family of 
heterotrimeric G proteins (141-143).  Gβγ dimers released from heterotrimeric G 
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proteins of the Gi family also activate PLC-β2 and PLC-β3 (23;144;145).  PLC-ε is a 
recently identified isozyme containing a CDC25 Ras-GEF domain at its amino 
terminus and two tandem Ras-associating (RA) domains at its carboxyl terminus.  
Rho and Ras family GTPases activate PLC-ε by two distinct mechanisms (173-177). 
We report here the identification of two members of a new class of 
phospholipase C enzyme and describe the molecular cloning and characterization of 
one of these proteins, PLC-η2.  This enzyme is activated by Gβγ subunits of 
heterotrimeric G proteins. 
2.3 Experimental 
Materials 
Inositol-free medium was purchased from ICN biochemicals (Costa Mesa, CA).  
[3H]Labeled phosphoinositide substrates were prepared from [3H]inositol-labeled 
turkey erythrocytes as described previously (143).  The 1kb DNA ladder was 
purchased from Promega (Madison, WI). 
The SuperScriptTM First-Strand Synthesis System for RT-PCR was obtained 
from Invitrogen (Carlsbad, CA).  The Marathon-ReadyTM cDNA kit was obtained 
from Clontech BD Biosciences (Mountain View, CA), which includes Marathon-Ready 
human retina cDNA (0.1 ng/μl in Tricine-EDTA buffer). 
The gene-specific primers and adaptor primers used for cloning of human 
PLC-η2 were as follows:  
CCATCCTAATACGACTCACTATAGGGC (adaptor primer, P1),  
ACTCACTATAGGGCTCGAGCGGC (adaptor primer, P2), 
GGACATCATCTTGTAGAAGGCACAGA (P3), 
CGTGGAGTCTGGGGAGGATGCCG (P4) and 
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GCCTCTTCCATCCCTTCTAGGTACA (P5). 
 The gene-specific primers used for RT-PCR of carboxyl terminal of mouse 
PLC-η2 were as follows: 
 CAAAAGCCAGAAGCCAAGTC (21 S), 
 AGGGATTGAGACCTGCGAGT (22 S), 
 CTCGCAGGTCTCAATCCCTA (22 AS), 
 ATCTCAGGAAGGGTCCCAGT (23 S), 
 TCTTCCAGAAGTCCCCTCAG (23 AS), 
 AGGGTATCCCCTCTTGGAGA (21c S) and 
 TCTCCAAGAGGGGATACCCT (21c AS). 
 A specific PLC-η2 antibody was generated against the peptide sequence 
KGSKLKKAASVEEGDEG within the X-Y linker region of human PLC-η2 (Quality 
Controlled Biochemicals, MA). 
Identification of the novel PLC-η sequences 
The basic local alignment search tool (BLAST) was applied to screen the 
non-redundant NCBI database (www.ncbi.nlm.nih.gov) for novel sequences with 
homology to the sequence in the conserved catalytic core of known PLC isozymes.  
Two unique sequences were identified and submitted to the BLAT search engine on 
the Santa Cruz genome browser (www.genome.ucsc.edu).  The position of each of 
these unique sequences was identified in human genomic sequence, and six human 
expressed sequence tags (ESTs), which mapped to the same genomic region as one 
of these novel genes (designated PLC-η2), were obtained from ATCC (Manassas, 
CA) and sequenced.  The protein sequence corresponding to the ORF represented 
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by one EST, BU178908, was submitted to the SMART website 
(www.smart.embl-heidelberg.de) for protein domain prediction.  
RACE PCR 
A gene-specific primer (P3 or P5) and P1 adaptor primer were used to amplify 
the 5’ end of human PLC-η2 using human retina cDNA (Marathon RACE kit; Clontech 
BD Biosciences) as a template.  Gene-specific primers (P4 and P5) were used to 
amplify a 1 kb product as an internal positive control for the presence of PLC-η2 
transcript.  PCR products from RACE reactions were gel-extracted, cloned into 
pCR2.1-TOPO vector (Invitrogen), and transformed into TOP10 competent cells 
(Invitrogen).  Plasmids were isolated from bacterial cultures with QIAprep Spin 
Miniprep kit (Qiagen) and sequenced at the UNC DNA sequencing facility.  
Construction of human PLC-η2 cDNA 
A chimera of EST1 and EST2 was constructed by ligating the two sequences 
at an internal BamHI site present in both ESTs.  This chimeric sequence is referred 
to as construct 1’-23 and contains exon 1’ and exons 2-23.  A second human 
PLC-η2 cDNA sequence was then constructed by joining the 5’-RACE PCR product 
with the EST1/EST2 chimera at the unique BglII restriction site (Fig. 1).  This 
sequence is referred to as construct 1-23 and contains exon 1 and exons 2-23.  A 
third construct corresponding to exon 2-23 with an exogenously added ATG start 
codon also was constructed.  All three constructs were cloned into pcDNA4, which 
incorporates a His6 tag at the carboxyl terminus.  
RT-PCR 
Individual mouse tissues (brain, eye, and lung) were resuspended in TRIzol 
reagent (Invitrogen).  Following addition of chloroform, the aqueous and organic 
phases were separated by centrifugation at 14,000g at 4˚C for 15 min.  The aqueous 
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portion containing RNA was combined with isopropanol to precipitate RNA, and the 
sample was centrifuged at 14,000g at 4˚C for 10 min.  The RNA pellet was then 
washed in 1 ml of 75% ethanol, dried, and resuspended in diethyl pyrocarbonate 
(DEPC)-treated dH2O.  The concentration of total RNA was determined by 
measuring its optical density (OD) at 260 nm.  Up to 5 μg of total RNA was used in a 
reverse transcription reaction with oligo dT primer and 1 μl of 10 mM dNTP mix, 
which was heated to 65˚C for 5 min and chilled on ice for at least 1 min.  A mixture of 
10X reverse transcription buffer, 25 mM MgCl2, 0.1 M dithiothreitol (DTT), and 
RNaseOUT was added to the above RNA mix and incubated at 42˚C for 2 min.  One 
μl of reverse transcriptase (Invitrogen) was added and the reaction was carried out at 
42˚C for 50 min.  Reverse transcription was terminated by incubation at 70˚C for 15 
min.  One μl of E. coli RNase H was used to degrade the template RNA and leave 
first strand cDNA.  Two μl of this cDNA were then used in each PCR reaction for 
amplification using gene-specific primers 21S, 22S, 22AS, 23S, 23AS, 21cS, and 
21cAS. 
In vitro phospholipase C assay 
PLC-η2(1-23, 1’-23, or 2-23) or PLC-β2 was transiently expressed in COS-7 
cells.  Cells were harvested 48 h after transfection using hypotonic buffer with 
protease inhibitors (leupeptin, aprotonin, TPCK, and PMSF).  The soluble fraction 
was obtained by centrifugation at 100,000g for 30 min at 4˚C.  The total protein 
concentration of the soluble fraction was determined by BioRad protein assay 
(BioRad).  Phospholipase C assays included 5 nmol PtdIns(4)P or PtdIns(4,5)P2 
(Avanti Polar Lipids, AL) and 10,000 cpm [3H]PtdIns(4)P (prepared from 
[3H]inositol-labeled turkey erythrocytes as described previously (143)) in final buffer 
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conditions including 10 mM HEPES, pH 7.4, 120 mM KCl, 10 mM NaCl, 2 mM EGTA, 
5.8 mM MgSO4, 0.5% cholate, and 100 μM free calcium in a final volume of 50 μl. 
Assays were incubated at 30˚C for 10 min and were terminated by adding 200 μl of 
10% trichloroacetic acid and 100 μl of 10 mg/ml bovine serum albumin (BSA).  
[3H]Inositol (1,4)-bisphosphate was quantified by liquid scintillation counting of the 
soluble fraction after centrifugation of the reaction mixture. 
In vivo phospholipase C assay 
COS-7 cells were seeded in 96-well plates at a density of 8,000 cells per well 
and maintained in DMEM supplemented with 10% fetal bovine serum (FBS) at 37˚C 
in an atmosphere of 90% air/10% CO2.  PLC-β1, PLC-β2, PLC-ε, or PLC-η2(2-23) 
plasmid DNA was transfected into COS-7 cells in the absence or presence of 
expression vectors for Gα subunits, Gβγ subunits, or small GTPases using Fugene 6 
(Roche) transfection reagent according to the manufacturer’s protocol.  The medium 
was changed to inositol-free DMEM containing 1 μCi of [3H]inositol/well 24 h after 
transfection.  After an additional 12 h incubation, [3H]inositol phosphate 
accumulation was initiated by addition of LiCl to a final concentration of 10 mM.  The 
reaction was stopped after 60 min by aspiration of the medium and the addition of 
50 mM ice cold formic acid.  [3H]inositol phosphates were quantified as previously 
described (209). 
Western Blots 
 COS-7 cell lysates coexpressing PLC-η2 and Gβ1γ2 were collected in 20 mM 
HEPES buffer, pH 7.4 with protease inhibitors (TPCK, PMSF, aprotonin, and 
leupeptin).  The soluble fraction was obtained by centrifugation at 100,000g for 30 
min at 4˚C.  The total protein concentration of the soluble fraction was determined by 
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BioRad protein assay (BioRad).  Equivalent samples were loaded and 
immunoreactivity of PLC-η2 was detected by polyclonal anti-His antibody.  
 Whole cell lysates from 1321N1 human astrocytoma cells were collected in 20 
mM HEPES buffer, pH 7.4 with protease inhibitors (TPCK, PMSF, aprotonin, and 
leupeptin).  The soluble fraction was obtained by centrifugation at 13,000 rpm for 20 
min at 4˚C.  Equivalent samples of the whole cell lysates and the soluble fraction 
were loaded and immunoreactivity of PLC-η2 was detected by polyclonal PLC-η2 
antibody with or without the specific peptide used for PLC-η2 antibody generation.  
COS-7 cell lysates expressing PLC-η2(2-23) was used as positive control. 
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2.4 Results 
With the goal of identifying novel phospholipase C isozymes, we conducted 
BLAST searches against the non-redundant NCBI DNA database to identify novel 
sequences with homology to sequence in the conserved catalytic core of known PLC 
isozymes.  Two unique sequences were identified and submitted to the BLAT search 
engine on the Santa Cruz genome browser.  The sequences mapped to the human 
genome at positions 1p36.32 and 3q25.31.  One of these, PLC-η1 (3q25.31), was 
recently reported by Hwang et. al. (82), and therefore is not the focus of this 
manuscript.  Our studies focused on the gene that mapped to 1p36.32, designated 
PLC-η2.   
Although no apparent full-length genes were indicated in the 1p36.32 
sub-region (base position 2435000-2470000), several predictive algorithms 
suggested the existence of open reading frames.  Additionally, many expressed 
sequence tags (ESTs) mapped to this sub-region, and six of these ESTs were 
obtained and sequenced.  Two of these, BU178908 (EST1) and BE908459 (EST2), 
contained nearly full-length sequences of PLC-η2 with two exceptions.  First, a 
deletion of 146 bp in exon 23 in BU178908 (not observed in other ESTs) resulted in a 
frame shift and consequently introduced an early stop codon, and second, a missing 
exon (exon 16) in BE908459 (present in all other ESTs) (Figure 2.1A).  Moreover, 
five other ESTs and mRNAs identified from the UCSC genome browser also matched 
the PLC-η2 sequence from exon 13 to the end of the gene, strongly suggesting that 
the two exceptions mentioned above are artifacts.  Thus, sequences of BU178908 
and BE908459 were combined at a unique BamHI site to form a cDNA (EST1/EST2 
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chimera) encoding a 1389 amino acid protein (Figure 2.1A).  The protein sequence 
of the EST1/EST2 chimera was submitted to the SMART website, which predicted 
the presence of a PH domain, four EF hand domains (the latter two were predicted by 
3D-PSSM algorithm), a catalytic TIM barrel, and a C2 domain.  Thus, the unique 
sequence of PLC-η2 is comprised of the canonical domains of a PLC isozyme.  
PLC-η2 contains a long carboxyl terminal region, within which no obvious domain is 
predicted.  However, a class II PDZ-binding motif, LLRL, is present at the carboxyl 
terminus of PLC-η2 (Figure 2.1A) (210;211), which is conserved in mouse PLC-η2 
sequence as well as both human and mouse sequences of PLC-η1. 
Further analysis of the genomic sequence revealed that PLC-η2 is comprised 
of at least 23 exons, designated here 1’ through 23 (Figure 2.1B).  Exon 1’ is 
designated for the reason explained below in Figure 2.2.  A more detailed illustration 
of the 3’-end of PLC-η2 including alternatively spliced exon 22 is shown below in 
Figure 2.4.  Since most mammalian genes contain a stop codon in frame with the 
start methionine in the 5’ untranslated region (UTR) of the gene sequence, we further 
analyzed the first exon of this EST chimera.  Absence of a stop codon in frame with 
the start methionine (Figure 2.1B) suggested that additional coding sequence might 
exist 5’ to the first exon in the chimera.  Therefore, 5’-RACE PCR was used to clone 
the 5’ end of PLC-η2.  A gene-specific primer (P3) and a RACE adaptor primer (P1) 
were used to amplify the 5’ end of the gene using human retina cDNA as a template 
(Figure 2.2A).  PCR resulted in amplification of an approximate 1 kb fragment 
corresponding to a new exon (designated exon 1) and exons 2 through 5 (Figure 
2.2B).  Further analysis of this newly identified first exon revealed two upstream stop 
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codons in frame with a start methionine, suggesting that this ATG is the correct start 
site (Figure 2.2B).  A construct corresponding to exon 1 and exons 2-23 was 
generated by joining the newly identified 5’ end with the chimera sequence at the 
common BglII site to form a 4248 bp cDNA encoding a 1416 amino acid protein 
predicted to be 155 kDa.  Analysis of the genomic sequence at 1p36.32 revealed 
that the first exon from the EST chimera (designated exon 1’) lies 8900 bp upstream 
of the first exon identified by RACE PCR (Figure 2.2C).  In addition, an identical 
5’-sequence, encompassing exon 1 through exon 5 was cloned from a human kidney 
cDNA library (data not shown).  Mammalian expression vectors (in pcDNA4 with a 
His6 tag at the carboxyl terminus) were generated for three different constructs (1-23, 
1’-23, and 2-23) of PLC-η2.  These are graphically illustrated in Figure 2.2D. 
The amino acid sequence of human PLC-η2(1-23) was aligned with its mouse 
ortholog in Figure 2.3.  This mouse ortholog of PLC-η2 is 77.7% identical in overall 
sequence to human PLC-η2, 92.4% identical in sequence from PH to C2 domain, 
and 66.4% identical in the carboxyl tail.  The first exon (exon 1) of human PLC-η2 is 
well conserved in its mouse ortholog.  However, since no stop codons are present 
upstream of the equivalent methionine in mouse PLC-η2, the coding sequence of the 
first exon in mouse PLC-η2 potentially begins at a methionine present 75 residues 5’ 
to the first methionine of human PLC-η2.  Human PLC-η2 is 41.3% identical in 
overall sequence to human PLC-η1, 66.9% identical in sequence from PH to C2 
domain, and 17.4% in the carboxyl tail sequence (Figure 2.3).  Therefore, the 
PLC-η1 and PLC-η2 sequences are well conserved in their catalytic core, but 
PLC-η1 apparently contains additional sequence in the carboxyl terminal region 
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beyond the C2 domain.  The PDZ-binding domain, LLRL, is conserved in both 
PLC-η1 and PLC-η2 from Fugu to human, suggesting a potential interaction site for 
other signaling proteins. 
 The form of human PLC-η2 identified and characterized in this study and the 
mouse sequence of PLC-η2 illustrated in Figure 2.3 both differ from that recently 
reported by Nakahara et al. within the carboxyl terminus (83).  This difference is due 
to alternative splicing, and Figure 2.4A illustrates five predicted splice variants at the 
carboxyl terminus of the mouse gene.  For example, 21a/23 refers to a splice form 
containing exon 21a and exon 23, and both human and mouse PLC-η2 sequences 
shown in Figure 2.3 are 21a/23 splice forms.  Other potential splice forms include 
21a/22/23, 21b/23, 21b/22/23 and 21c/22/23.  Both exon 22 and exon 21c encode 
in-frame stop codons, which would result in smaller proteins.  The amino acid 
sequence encoded by each exon is listed in Figure 2.4B. 
Differences between the form of human PLC-η2 identified and studied here 
and that reported from mouse by Nakahara et al. (83) prompted us to examine mouse 
RNA for the potential existence of multiple forms including exon usage that would 
encode the sequence illustrated in Figure 2.3.  Primers designed to each carboxyl 
terminal exon were applied in RT-PCR analyses of cDNA reverse-transcribed from 
total RNA extracted from mouse eye, brain, and lung to distinguish potential splice 
forms mentioned above.  The table below summarizes protein sizes and mouse 
tissue distribution of five splice variants. 
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Splice form Protein, aa Molecular weight, kDa Tissue 
 Human Mouse Human Mouse Mouse 
21a/23 1416 1501 154.7 164.3 eye, lung 
21a/22/23 989 1070 110.2 119.2 eye 
21b/23 1583 1669 171.7 181.4 ? 
21b/22/23 1156 1238 127.2 136.3 eye, brain 
21c/22/23 1211 1252 132.8 137.7 eye, brain 
21c/23 1211 1252 132.8 137.7 ? 
Table 2.1. Summary of splice variants of PLC-η2. 
 
Only the 21a/23 splice form (no other variants) was observed in mouse lung (Figure 
2.5).  RT-PCR analyses of mouse brain cDNA revealed the presence of the 
21b/22/23 splice form as determined with gene specific primers (i.e. 21S and 23AS; 
21S and 22AS).  This 21b/22/23 form was reported by Nakahara et al.(83).  The 
21c/22/23 form was not observed in cDNA from mouse brain, eye, or lung using the 
above primers, but gene specific primers directed toward exon 21c (21S and 21cAS, 
21cS and 22AS) revealed presence of the 21c/22/23 form in mouse eye and brain.  
In contrast, four splice forms were observed in mouse eye.  The potential splice 
forms 21b/23 and 21c/23 were not observed in our RT-PCR analysis.  In summary, 
both the mouse sequence reported by Nakahara et al. (83)and the human PLC-η2 
sequence studied here appear to be legitimate spliced forms of mouse PLC-η2.  
Similar to mouse PLC-η2, all of the above splice forms are possible in human. 
Our results indicate that the human PLC-η2 reported here is equivalent to the mouse 
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PLC-η2 21a/23 splice form.  With the goal of identifying expressed forms of native 
human PLC-η2, we generated PLC-η2 specific antisera against a conserved 
sequence (KGSKLKKAASVEEGDEG) in the catalytic core of PLC-η2 that is unique 
to this isozyme.  This antisera readily detected a species of approximately 155 kDa 
in COS-7 cells expressing recombinant human PLC-η2(2-23) (Figure 2.6).  This 
immunoreactive species was not observed in empty vector-transfected COS-7 cells 
(data not shown).  A similar 155 kDa immunoreactive species also was observed 
natively expressed in 1321N1 human astrocytoma cells.  Specific peptide used for 
PLC-η2 antibody generation blocked the immunoreactivity associated with the 
approximately 155 kDa species expressed in COS-7 cells transfected with an 
expression vector for human PLC-η2 as well as the immunoreactive species 
expressed natively in 1321N1 cells.  These results with antisera against human 
PLC-η2 are consistent with expression of both a recombinant and a natively 
expressed 155 kDa protein corresponding to the 21a/23 splice form of PLC-η2.  
Exon specific primers also indicated the presence of multiple splice forms in RT-PCR 
analyses of cDNA reverse-transcribed from total RNA extracted from human 1321N1 
cells and human SH-SY5Y cells (data not shown). 
The potential activity of PLC-η2 as a functional phospholipase C was tested in 
vitro.  PLC-η2(1-23, 1’-23, or 2-23) or PLC-β2 was transiently expressed in COS-7 
cells, and the soluble fraction was isolated from cell lysates.  Phospholipase C 
activity was quantified as described in Methods in the presence of [3H]PtdIns(4)P, 
0.5% cholate, and increasing amounts of total cytosolic protein.  A 5-10 fold increase 
in phospholipase activity was observed in homogenates of cells expressing either 
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PLC-η2(1’-23) or PLC-η2(2-23) (Figure 2.7A).  An approximately 2-fold increase 
was observed for the cytosolic fraction obtained from COS-7 cells expressing 
PLC-η2(1-23) (Figure 2.7A).  Similar results were obtained using [3H]PtdIns(4,5)P2 
as substrate (data not shown).  Western blots revealed that similar amounts of 
PLC-η2(1-23), PLC-η2(1’-23), PLC-η2(2-23), and PLC-β2 were expressed under the 
conditions of these experiments (data not shown).  The concentration of cholate 
(0.5%) used in these assays is optimal for quantification of the activity of PLC-β2, and 
therefore, we tested PLC-η2 phospholipase activity at this cholate concentration.  
However, under these assay conditions PLC-β2 exhibited enzyme activities 
approximately two fold greater than those of PLC-η2(1’-23) or PLC-η2(2-23).  In 
contrast, higher activities of the PLC-η2 constructs relative to that of PLC-β2 were 
observed in the absence of detergent or with lower concentrations of cholate (Figure 
2.7B).  Taken together these results illustrate that PLC-η2 functions as an active 
phospholipase C against phosphoinositide substrate and suggest that the basal 
activities of the PLC-η2(1’-23) and PLC-η2(2-23) constructs are greater than that of 
PLC-η2(1-23). 
To determine whether PLC-η2 is activated by G-proteins, we coexpressed 
PLC-η2(2-23) with GTPase-deficient mutants of various Gα-subunits and Ras 
superfamily GTPases and measured [3H]inositol phosphate accumulation as 
described in Methods.  PLC-β1, PLC-β2, and PLC-ε, which are known downstream 
effectors of certain G proteins (23;143;175), also were coexpressed with 
corresponding G proteins as positive controls.  The construct PLC-η2(2-23) was 
used in these assays because it elicits robust lipase activity (Figure 2.8) and contains 
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sequence common to all constructs.  Expression of PLC-η2(2-23) alone increased 
basal [3H]inositol phosphate accumulation by as much as 2 fold.  Under the 
conditions tested, wild type Gαq activated PLC-β1, and the GTPase deficient mutants 
of Gα12(Q226L) and Gα13(Q229L) activated PLC-ε (Figure 2.8A).  As expected, 
expression of RhoA, RhoB, or RhoC significantly increased [3H]inositol phosphate 
accumulation in COS-7 cells expressing PLC-ε, while expression of Rac1, Rac2, or 
Rac3 activated  PLC-β2 (Figure 2.8B).  In contrast, no activation of PLC-η2(2-23) 
was observed following coexpression with any of the Gα-subunits (wild-type Gαq, 
Gα11, Gα14, Gα15/16 and QL mutants of Gαq, Gα11, Gα14, Gα15/16, Gα12, Gα13, Gαs, 
Gαolf, Gαi1, Gαi2, Gαi3, GαoA, GαoB, Gαrod, and Gαcone) or Ras superfamily GTPases 
(RhoA, RhoB, RhoC, Rac1, Rac2, Rac3, Cdc42, Cdc42p, TCL, TC10, RhoG, RhoD, 
Rnd1, Rap1A, Rap1B, Rap2A, and Rap2B) tested (Figure 2.8 and data not shown).  
Thus, although activation of PLC-η2(2-23) may occur downstream of certain 
Gα-subunits or Ras family GTPases, no evidence for such activation was revealed 
under the conditions of our assays. 
The capacity of Gβγ to activate PLC-η2 also was examined in COS-7 cells.  
As illustrated in Figure 2.9, coexpression of increasing amounts of PLC-η2(2-23) with 
Gβ1γ2 resulted in marked elevation of [3H]inositol phosphates compared to cells 
expressing PLC-η2(2-23) alone.  The extent of activation of PLC-η2(2-23) was at 
least as large as that observed with PLC-ε under the same conditions.  Expression 
of soluble PLC-η2(2-23), corresponding to a 155 kDa band on the immunoblot, did 
not increase as a consequence of expression of Gβγ (Figure 2.9, inset), indicating 
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that the increased activity of PLC-η2(2-23) is a result of Gβγ-promoted activation 
rather than due to a change in expression of PLC-η2(2-23). 
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2.5 Discussion 
The work described here illustrates the existence of a new isoform of 
phospholipase C termed PLC-η2.  This isozyme contains the conserved domains 
found in the catalytic core of all PLC isozymes and also contains a long carboxyl 
terminal region.  Coexpression of PLC-η2 with Gβ1γ2 resulted in a robust increase in 
inositol lipid hydrolysis, and therefore, this isozyme may in part function downstream 
of G protein-coupled receptors. 
Most of the coding sequence of PLC-η2 was constructed from two ESTs, the 
validity of which was confirmed in the carboxyl terminal half of the isozyme by the 
existence of multiple mRNAs in the database exhibiting identical sequences.  Our 
5’-RACE analyses using either human retina or kidney cDNA identified an upstream 
exon (exon 1) not present in available ESTs or mRNA data.  Indeed, the first exon 
(exon 1’) present in EST1 (BU178908) exists far upstream (8900 bp) of the coding 
sequence we amplified by 5’-RACE.  The sequence amplified from both retinal and 
kidney cDNA is encoded by a new exon (exon 1) with two stop codons in the 5’ UTR 
in frame with a start methionine and by exon 2 through exon 5.  Thus, an isozyme 
transcribed from exon 1 through exon 23 is at least one form of this novel PLC 
expressed in human tissues.  
Although no functional data were reported, Stewart et al. (84) recently 
recognized a sequence for PLC-η2 in the available human DNA database.  The 5’ 
end of the gene proposed by Stewart and coworkers potentially represents a splice 
variant of PLC-η2 since it differs markedly at the first exon from that confirmed in our 
5’- RACE analyses of human cDNA.  However, it is unclear from our analyses of 
 69
genomic structure how this splice variant would be formed.  Moreover, although the 
5’ end of PLC-η2 encoded by exon 1 (Figure 2.2) was amplified from two sources of 
human cDNA (retina and kidney), we have failed to amplify the 5’ sequence 
suggested by Stewart and coworkers applying various primers constructed on the 
basis of the unique 5’ end of PLC-η2 reported by Stewart and coworkers (data not 
shown). 
 Alternative splicing also occurs in the carboxyl terminus of PLC-η2.  Indeed, the 
form of mouse PLC-η2 recently cloned and studied by Nakahara et al. (83) differs in 
exon usage in the carboxyl terminal region from the human PLC-η2 we have cloned 
and studied.  Although no apparent domains or obvious tertiary structure exists in 
this portion of the isozyme, our observation of multiple modes of exon usage and 
tissue specific expression of carboxyl terminal variants of PLC-η2 suggest important 
functionality in the carboxyl terminal region of the isozyme.  For example, mouse 
lung exclusively expresses the 21a/23 form suggesting that the carboxyl terminal 
region may be important for the enzyme to function or interact with other proteins in 
epithelial tissues.  This form ends with the potential PDZ domain-binding motif LLRL 
at its extreme carboxyl terminus, which ostensibly confers specific protein-protein 
interactions for lung PLC-η2.  Mouse brain expresses both the 21b/22/23 and 
21c/22/23 splice forms.  The former variant has an in-frame stop codon in exon 22, 
which renders exon 23 as untranslated sequence.  The latter form contains an 
in-frame stop codon in exon 21c, which renders both exons 22 and 23 untranslated.  
These two forms may play important roles in neuronal function.   Mouse eye 
expresses four alternative splice forms (21a/23, 21a/22/23, 21b/22/23 and 21c/22/23), 
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and it will be important to establish whether, for example, these exhibit different 
functional activities, interact with different regulatory proteins, are expressed in 
different development stages, are expressed in different pools of retinal cells, and/or 
are localized to different subcellular compartments. 
Phospholipase C activity was observed with three different constructs of 
PLC-η2, and the activities observed both in vitro and in vivo are on the order of that 
quantified with PLC-β2 and other PLC isozymes under similar conditions.  
Interestingly, the PLC-η2 constructs comprising exons 2-23 or 1’-23 exhibited several 
fold higher phospholipase activity than the PLC-η2(1-23) construct.  We believe that 
these data reflect true differences in the activity of these isozyme forms since similar 
amounts of soluble and supposedly fully folded protein were expressed and 
compared among the three constructs.  Thus, one interpretation of these results is 
that the presence of exon 1 leads to a decrease in lipase activity in both in vitro and in 
vivo measurements of enzyme activity.  No precedent exists for autoinhibition of a 
phospholipase C enzyme, and potential mechanisms whereby the sequence 
provided by exon 1 would inhibit lipase activity are not obvious. 
 Sequence analyses of PLC-η2 revealed all of the canonical domains of a 
PLC isozyme with an additional long carboxyl terminus that contains a PDZ 
domain-binding motif, LLRL.  Members of the PLC-β family containing PDZ 
domain-binding motifs at their carboxyl termini have been shown to interact with PDZ 
domain-containing proteins including the Na+/H+ exchanger regulatory factor (NHERF) 
(168;169).  NHERF acts as a scaffolding protein that augments the signal from a 
G-protein coupled receptor, parathyroid hormone 1 receptor (PTH1R), to PLC-β 
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enzymes in response to parathyroid hormone (170;171).  Whether this motif in 
PLC-η2 has unique functionality and whether it serves as an interaction site for an 
upstream activator, a downstream interacting protein, a scaffold protein-binding site, 
or some other function needs to be determined. 
Activation of PLC-η2(2-23) by Gα subunits of heterotrimeric G proteins or by 
Ras superfamily GTPases was not observed under the conditions of our assays.  
Although predictable activation of PLC-β and PLC-ε isozymes by G proteins was 
observed, our results do not unequivocally rule out the possibility that PLC-η2 lies 
downstream of signaling pathways promoted by these or other Gα subunits or Ras 
GTPases.  On the other hand, our experiments revealed robust activation of PLC-η2 
by Gβγ, and this isozyme, like PLC-β2, PLC-β3 (23;144;145), and PLC-ε (176), 
apparently functions downstream of G protein coupled receptors that release Gβγ 
through activation of heterotrimeric G proteins, particularly those of the Gi family.  An 
important current goal is to purify PLC-η2 to homogeneity and to establish whether 
Gβγ or possibly other G proteins activates this isozyme by a direct mechanism.  
Protein sequences in the catalytic core are well conserved between human 
PLC-η2 and human PLC-η1 (Figure 2.3).  Hwang and coworkers have recently 
reported the identification of human PLC-η1, in which the exon arrangement (82) is 
similar to that of human PLC-η2 in our studies.  Based on the sequence alignment 
illustrated in Figure 2.3, PLC-η1 sequence lacks the first exon, and therefore its 
coding sequence begins with the PH domain.  Sequences of PLC-η1 diverge from 
those of PLC-η2 in the carboxyl terminus in that PLC-η1 contains four inserted 
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regions resulting in an additional 300 amino acids (Figure 2.3).  BLAST analysis of 
the carboxyl tails of both PLC-η1 and PLC-η2 yields no homology to any other 
proteins in the human database.  The significance of this difference needs further 
investigation, and whether the extra sequence in PLC-η1 renders different modes of 
regulation will be explored further.   
We have not carried out a systematic and rigorous analysis of the presence of 
PLC-η2 in human tissues.  However, we know from our PCR analyses that the 
distribution is relatively broad since PLC-η2 RNA is expressed both in human kidney 
and retina, as well as in mouse brain, eye, and lung.  PLC-η2 is natively expressed 
as an approximately 155 kDa immunoreactive species in 1321N1 human 
astrocytoma cells.  This size corresponds to the molecular size of the PLC-η2(2-23) 
construct utilized in our characterization of enzymatic activities of human PLC-η2. 
2.6 Summary 
In conclusion, a second member of the subclass of PLC isozymes designated 
as PLC-η has been identified, cloned, and shown to be activated by Gβγ-subunits of 
heterotrimeric G proteins.  At least thirteen different PLC isozymes now are known 
to exist in mammalian tissues, but our knowledge of the relative roles played by these 
signaling proteins remains rudimentary.  The activities of these isozymes clearly are 
regulated in multiple subcellular compartments by multiple mechanisms.  Moreover, 
we increasingly realize that various membrane phosphoinositides play important 
roles in cell signaling in addition to the historically considered production of 
Ins(1,4,5)P3 and diacylglycerol from PtdIns(4,5)P2.  Thus, it is imperative that we 
begin to unravel the functions of PLC-η2 and other PLC isozymes at the cellular level.  
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Figure 2.1. Identification of a new PLC isozyme, PLC-η2. 
A. EST chimera construction and predicted canonical domains of PLC-η2.  A 
BLAST search of the non-redundant NCBI DNA database was conducted, and two 
novel sequences were identified with homology to sequence in the conserved 
catalytic core of known PLC isozymes.  One of these genes was mapped to human 
chromosome 1p36.32, and two ESTs (BU178908 and BE908459) encompassed 
most of the coding sequence of this gene.  Because both ESTs contain a sequence 
error, they were combined at a common BamHI site to yield a chimeric cDNA of 4189 
bp, representing a 1389 amino acid protein.  The predicted sequence contains the 
canonical PH domain, four EF hands, an X and Y catalytic TIM barrel, and a C2 
domain of a PLC isozyme.  A PDZ binding motif, LLRL, is present at the carboxyl 
terminus of the chimeric sequence.  B. Analysis of first exon of EST chimera. 
Analysis of the genomic sequence revealed that PLC-η2 is composed of at least 23 
exons.  Inspection of the first exon of the EST chimera revealed no in frame stop 
codon upstream of the first ATG (bolded and underlined), suggesting that extra 
sequence exists upstream of the chimera. 
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Figure 2.2. Identification of the first exon of human PLC-η2. 
A. Amplification of sequence at the 5’ end of PLC-η2.  5’- RACE PCR was used 
to clone the 5’ end of PLC-η2 using the P1 adaptor primer and the gene-specific 
primer P3.  Gene-specific primers P4 and P5 were used to yield an approximate 1 
kb product as an internal positive control.  B. Sequence of new exon of PLC-η2.  
Human retina cDNA was used as a template, and a 1 kb product was generated that 
corresponded to a new first exon and exons 2-5. Analysis of the genomic sequence 
identified a start ATG and two in-frame stop codons residing in the 5’ UTR region.  
This newly identified exon was termed exon 1, and the first exon in the chimera was 
termed exon 1’.  C. Genomic organization of the PLC-η2 gene.  The horizontal 
bar represents the genomic sequence 1p36.32 (base position 2435000-2470000).  
The vertical bars represent exons of PLC-η2. Exon 1’ (present in the EST BU178908) 
lies 8900 bp 5’ to exon 1 (identified from 5’ RACE PCR) in the genomic sequence. D. 
Three constructs of PLC-η2 using different exons at the amino terminus.  
Three PLC-η2 constructs are graphically represented in this figure. PLC-η2(1-23) 
represents exon 1 and exons 2-23. PLC-η2(1’-23) represents exon 1’ and exons 2-23.  
PLC-η2(2-23) represents exons 2-23. In exon 1 and exon 1’, non-coding sequences 
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are represented by hatched symbols.  All three constructs were cloned into pcDNA4 
vector with a carboxyl terminal His6 tag. 
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hPLC-eta1  .......................................................................................................................M 1    
mPLC-eta1  ........................................................................................................................ 1    
hPLC-eta2  ..........................................................................MSGPWPSPDSRTKGTVAWLAEVLLWVGGSVVLSSEWQLGPLVERCM 46   
mPLC-eta2  MGGLAWGPSRAAGSSWVNASGTWEQPLRGFSGLQGGRRRGRGEKGIPEEPLCQLTPQLGLSLRVPFGLGDYGLDMPGPQPSAASQTTGAVACLAEVLLWVGGSVVVSPRWQLSLVVERCM 120  
 
 
hPLC-eta1  SVMQSGTQMIKLKRGTKGLVRLFYLDEHRTRLRWRPSRKSEKAKILIDSIYKVTEGRQSEIFHRQAEGNFDPSCCFTIYHGNHMESLDLITSNPEEARTWITGLKYLMAGISDEDSLAKR 121  
mPLC-eta1  ..MQSGTQMIKLKRGTKGLVRLFYLDEHRTRLRWRPSRKSEKAKILIDSIYKVTEGRQSEIFHRQAEGNFDPSCCFTIYHGNHMESLDLITSNPEEARTWITGLKYLMAGISDEDSLAKR 118  
hPLC-eta2  GAMQEGMQMVKLRGGSKGLVRFYYLDEHRSCIRWRPSRKNEKAKISIDSIQEVSEGRQSEVFQRYPDGSFDPNCCFSIYHGSHRESLDLVSTSSEVARTWVTGLRYLMAGISDEDSLARR 166  
mPLC-eta2  SAMQEGTQMVKLRGSSKGLVRFYYLDEHRSCLRWRPSRKNEKAKISIDSIQEVSEGRQSEIFQRYPDSSFDPNCCFSIYHGSHRESLDLVSPSSEEARTWVTGLRYLMAGISDEDSLARR 240 
 
 
 
hPLC-eta1  QRTHDQWVKQTFEEADKNGDGLLNIEEIHQLMHKLNVNLPRRKVRQMFQEADTDENQGTLTFEEFCVFYKMMSLRRDLYLLLLSYSDKKDHLTVEELAQFLKVEQKMNNVTTDYCLDIIK 241  
mPLC-eta1  QRTHDQWVKQTFEEADKNGDGLLNIEEIHQLMHKLNVNLPRRKVRQMFQEADTDENQGTLTFEEFCVFYKMMSLRRDLYLLLLSYSDKKDHLTVEELAQFLKVEQKMSNVTLDYCLDIIM 238  
hPLC-eta2  QRTRDQWLKQTFDEADKNGDGSLSIGEVLQLLHKLNVNLPRQRVKQMFREADTDDHQGTLGFEEFCAFYKMMSTRRDLYLLMLTYSNHKDHLDAASLQRFLQVEQKMAGVTLESCQDIIE 286  
mPLC-eta2  QRTRDQWLKQTFDEADKNGDGSLSISEVLQLLHKLNVNLPRQRVKQMFREADTDDHQGTLGFEEFCAFYKMMSTRRDLYLLMLTYSNHKDHLDASDLQRFLEVEQKMNGVTLESCQNIIE 360  
 
 
 
hPLC-eta1  KFEVSEENKVKNVLGIEGFTNFMRSPACDIFNPLHHEVYQDMDQPLCNYYIASSHNTYLTGDQLLSQSKVDMYARVLQEGCRCVEVDCWDGPDGEPVVHHGYTLTSKILFRDVVETINKH 361  
mPLC-eta1  KFEVSEENKVKNVLGIEGFTNFMRSPACDVFNPLHHEVYQDMDQPLCNYYIASSHNTYLTGDQLLSQSKVDMYARVLQEGCRCVEVDCWDGPDGEPVVHHGYTLTSKILFRDVVETINKH 358  
hPLC-eta2  QFEPCPENKSKGLLGIDGFTNYTRSPAGDIFNPEHHHVHQDMTQPLSHYFITSSHNTYLVGDQLMSQSRVDMYAWVLQAGCRCVEVDCWDGPDGEPIVHHGYTLTSKILFKDVIETINKY 406  
mPLC-eta2  QFEPCLENKSKGMLGIDGFTNYTRSPAGDIFNPEHNRVHQDMTQPLSHYFITSSHNTYLVGDQLMSQSRVDMYAWVLQAGCRCVEVDCWDGPDGEPIVHHGYTLTSKILFKDVIETINKY 480  
 
 
hPLC-eta1  AFVKNEFPVILSIENHCSIQQQRKIAQYLKGIFGDKLDLSSVDTGECKQLPSPQSLKGKILVKGKKLPYHLGDDAEEGEVSDEDSADEIEDECKFKLHYSNGTTEHQVESFIRKKLESLL 481  
mPLC-eta1  AFVKNEFPVILSIENHCSIQQQRKIAQYLKGILQDKLDLSSVDTGECRQLPSPQSLKGKILVKGKKLPYHLGDDAEEGEVSDEDSADEIEDECKFKLHYSNGTTEHQVESFIRKKLESLL 478  
hPLC-eta2  AFIKNEYPVILSIENHCSVIQQKKMAQYLTDILGDKLDLSSVSSEDATTLPSPQMLKGKILVKGKKLPANISEDAEEGEVSDEDSADEIDDDCKLLNGDAS.TNRKRVENTAKRKLDSLI 525  
mPLC-eta2  AFIKNEYPVILSIENHCSVVQQKKMAQYLTDILGDKLDLSSVSSEDATMLPSPQMLKGKILVKGKKLPANISEDAEEGEVSDEDSADEMEDDCKLLNGDAS.TNRKRVENIAKKKLDSLI 599  
 
hPLC-eta1  KESQIRDKEDPDSFTVRALLKATHEGLNAHLK....QSPDVKESG.....KKSHGRSLMTNFGKHKKTTKSRSKSYSTDDEEDTQQSTGKEGGQLYRLGRRRKTMKLCRELSDLVVYTNS 592  
mPLC-eta1  KESQIRDKEDPDSFTVRALLKATHEGLNAHLK....QNLDVKESG.....KKSHGRSLMANFGKHKKATKSRSKSYSTDDEDDSLQNPGKEGGQLYRLGRRRRTMKLCRELSDLVVYTNS 589  
hPLC-eta2  KESKIRDCEDPNNFSVSTLSPSGKLGR....K...SKAEEDVESGEDAGASRRNGRLVVGSFSRRKKKGSKLKKAASVEEGDEGQDSPG...GQSRGATRQKKTMKLSRALSDLVKYTKS 635  
mPLC-eta2  KESKIRDCEDPNDFSVSTLSPSGKLGRKAEAKKGQSKVEEDVEAGEDSGVSRQNSRLFMSSFSKRKKKGSKIKKVASVEEGDETLDSPG...SQSRGTARQKKTMKLSRALSDLVKYTKS 716  
 
 
hPLC-eta1  VAAQDIVDDGTT.GNVLSFSETRAHQVVQQKSEQFMIYNQKQLTRIYPSAYRIDSSNFNPLPYWNAGCQLVALNYQSEGRMMQLNRAKFKANGNCGYVLKPQQMCKGTFNPFSGDPLPAN 711  
mPLC-eta1  VAAQDIVDDGTT.GNVLSFSETRAHQVVQQKSEQFMIYNQKQLTRIYPSAYRIDSSNFNPLPYWNAGCQLVALNYQSEGRMMQINRAKFKANGNCGYILKPQQMCKGTFNPFSGDPLPAN 708  
hPLC-eta2  VATHDIEMEAASSWQVSSFSETKAHQILQQKPAQYLRFNQQQLSRIYPSSYRVDSSNYNPQPFWNAGCQMVALNYQSEGRMLQLNRAKFSANGGCGYVLKPGCMCQGVFNPNSEDPLPGQ 755  
mPLC-eta2  VGTHDVEIEVVSSWQVSSFSETKAHQILQQKPTQYLRFNQHQLSRIYPSSYRVDSSNYNPQPFWNAGCQMVALNYQSEGRMLQLNRAKFSANGDCGYVLKPQCMCQGVFNPNSEDPLPGQ 836  
 
 
 
hPLC-eta1  PKKQLILKVISGQQLPKPPDSMFGDRGEIIDPFVEVEIIGLPVDCCKDQTRVVDDNGFNPVWEETLTFTVHMPEIALVRFLVWDHDPIGRDFVGQRTVTFSSLVPGYRHVYLEGLTEASI 831  
mPLC-eta1  PKKQLILKVISGQQLPKPPDSMFGDRGEIIDPFVEVEIIGLPVDCCKDQTRVVDDNGFNPVWEETLTFTVHMPEIALVRFLVWDHDPIGRDFVGQRTVTFSSLVPGYRHVYLEGLTEASI 828  
hPLC-eta2  LKKQLVLRIISGQQLPKPRDSMLGDRGEIIDPFVEVEIIGLPVDCSREQTRVVDDNGFNPTWEETLVFMVHMPEIALVRFLVWDHDPIGRDFIGQRTLAFSSMMPGYRHVYLEGMEEASI 875  
mPLC-eta2  LKKQLALRIISGQQLPKPRDSVLGDRGEIIDPFVEVEVIGLPVDCSKEQTRVVDDNGFNPMWEETLVFTVHMPEIALVRFLVWDHDPIGRDFIGQRTLAFSSIMPGYRHVYLEGMEEASI 956  
 
 
hPLC-eta1  FVHITINEIYGKNRQLQGLKGLFNKNPRHSSSENNSHYVR..KRSIGDRILRRTASAPAKGRKKSKMGFQEMVEIKDSVSEATRDQDGVLRRTTRSLQARPVSMPVDRNLLGALSLPVSE 949  
mPLC-eta1  FVHITINEIFGKNRQLQGLKGLFNKNPRHASSENNSHYVR..KRSIGDRILRRTASAPAKGRKKSKVGFQEMVEIKDSVSEASRDQDGVLRRTTRSLQVRPVSMPVDKSLLGALSLPISE 946  
hPLC-eta2  FVHVAVSDISGKVKQALGLKGLFLRGPKPGSLDSHAAGRPPARPSVSQRILRRTASAPTKSQKPGRRGFPELVLGTRDTGSKGVADDVVPPGPGPAPEAPAQEGPGSGSPRDTRPLSTQR 995  
mPLC-eta2  FVHVAVSDISGKVKQTLGLKGLFLRGTKPGSLDSHAAGQPLPRPSVSQRLLRRTASAPTKSQKPSRKGFPELALGTQDAGSEGAADDVAPSSPNPALEAPTQERSGSSSPRDTRLFPLQR 1076 
 
hPLC-eta1  TAKDIEGKENSLAEDKDGRRKGKASIKDPHFLNFNKKLSSSSSALLHKDTSQGDTIVSTAHMSVTGEQLGMSSPRGGRTTSNATSNCQENPCPSKSLSPKQHLAPDPVVN.PTQDLHGVK 1068 
mPLC-eta1  AAKDTDGKENCLAGDKDDRRKGAATRKDPHFSNFNKKLSSSSSALLHKDANQGPTASVSNPEQCGGRGAKSE.....RIKPNMTNDCQENHNPPKFLSPRKHLALDPATKGLQERLHGMK 1061 
hPLC-eta2  PLPPLCSLETIAEEPAPG..........PGPPPPAAVPTSSSQGRPPYPTGPGANVASPLEDTE..............................EPRDSRPRPCNGEGAGGAYERAPGSQ 1075 
mPLC-eta2  PISPLCSLEPIAEEPALG..........PGLPLQAAAPTGPSQEGSQCPVGLGAKVTSSQQTSLGAFGTLQL................RIGGGRENEEPPLRPHNGGISSGPREGTSGRQ 1170 
 
hPLC-eta1  IKEKGNPEDFVEGKSILSGSVLSHSNLEIKNLEGNRGKGRAATSFSLSDVSMLCSDIPDLHSTAILQESVISHLIDNVTLTNENEPGSSISALIGQFDETNNQALTVVSHLHNTSVMSGH 1188 
mPLC-eta1  TNEKEHAEGFLGEKSMLSGSVLSQSSLEVENLEGSRAKGRAATSFSLSDVSALCSDIPDLHSTAILQDTEISNLIDDVTLTNENQSGSSISALIGQFEESNHPANVTVVSHLSTSGASGS 1181 
hPLC-eta2  TDGRS.............................................................................................QPRTLGHLPVIRRVKSEGQVPT 1102 
mPLC-eta2  TDSKS.............................................................................................RSRVPGHLPVVRRAKSEG.... 1193 
 
hPLC-eta1  CPLPSLGLKMPIKHGFCKGKSKSSFLCSSPELIALSSSETTKHATNTVYETTC.TPISKTKPDDDLSSKAKTAALESNLPGSPNTSRGWLPKSPTKGEDWETLKSCSPASSPDLTLEDVI 1307 
mPLC-eta1  APFQTP.....FKHGLSQGNQKASFLCSSPELNKLSSVETTKLANNAVPCGVIGSPISTPKPGDDPSDKAKTRVIEGNLPGFPDASPGQFPKSPTHGEDHSQVMNS.PALSTELAIEDII 1295 
hPLC-eta2  EPLGGW.........................................................RPLAAPFPAPAVYSDATGSDPLWQRLEPCG..........HRDSVSSSSSMSSSDTV 1155 
mPLC-eta2  ...............................................................QVLSELSPTPAVYSDATGTDRLWQRLEPGS..........HRDSVSSSSSMSSNDTV 1240 
 
hPLC-eta1  ADPTLCFNSGESSLVEIDGESENLSLTTCEYRREGTSQLASPLKLKYNQGVVEHFQRGLRNGYCKETLRPSVPEIFNNIQDVKTQSISYLAYQGAGFVHNHFSDSDAKMFQTCVPQQSSA 1427 
mPLC-eta1  ADPALSINSAESSLVEIDGESENLSLTTCDYREEAPSQLVSPLKLQQSQEMVEHIQRGLRNGYCKETLLP..SEIFNNIPGVKNHSISHLTYQGAGFVYNHFSSSDAKTNQICEPQQPRA 1413 
hPLC-eta2  IDLSLPSLGLGRSRENLAGAHMGRLPPRPHSASAARPDLPPVTKSKSNP....NLRATGQRPPIPDELQP............................................RSLAPR 1227 
mPLC-eta2  IDLSLPSLGLCRSRESIPGVSLGRLTSRPCLASAARPDLPPVTKSKSNP....NLRVAGGLPTAPDELQP............................................RPLAPR 1312 
 
hPLC-eta1  QDMHVPVPKQLAHLPLPALKLPSPCKSKSLGDLTSEDIACNFESKYQCISKSFVTTGIRDKKGVTVKTKSLEPIDALTEQLRKLVSFDQEDNCQVLYSKQDANQLPR...ALVRKLSSRS 1544 
mPLC-eta1  PDMHAPTPTPSTHAPLAALKLPSPCKSKSLGDLTSEDIACNFESKYQCISRSFVTNGIRDKS.VTMKTKSLEPLDALTEQLRKLVSFDQEDSCQVLYSKQDVNQCPR...ALVRKLSSRS 1529 
hPLC-eta2  MAGLPFRPPWGCLSLVGVQDCPVAAKSKSLGDLTADDFAPSFEGGSRRLSHSLGLPGGTRRV.....SGPGVRRDTLTEQLRWLTVFQQAGDITSPTSLGPAGEGVAGGPGFVRRSSSRS 1342 
mPLC-eta2  LTGHHPRPPWHHLTLVGLRDCPVSAKSKSLGDLTADDFAPSFQGSTSSLSCGLGSLGVAHQV.....LEPGIRRDALTEQLRWLTGFQQAGDITSPTSLGPAGDGSVGGPSFLRRSSSRS 1427 
 
hPLC-eta1  QSRVRNIASRAKEKQEANKQKVPNPSNGAGVVLRNKPSAPTPAVNRHSTGSYIAGYLKNTKGGGLEGRGIPEGACTALHYGHVDQFCSDNSVLQTEPSSDDKPEIYFLLRL    1655  
mPLC-eta1  QSRVRNIASRAKEKQEAGKQKAMAQSTRGGVVLRSKPPAPALAVNRHSTGSYIASYLRNMKAGGLEGRGIPEGACTALRYGYMDQFCSDNSVLQTEPSSEDKPEIYFLLRL    1640  
hPLC-eta2  HSRVRAIASRARQAQERQQRLQGLGR..................................QGPPEEERGTPEGACSVGHEGSVDAPAPSKGALGPASAAA~~~ENLVLLRL... 1416  
mPLC-eta2  QSRVRAIASRARQAQERQQRLRGQDS..................................RGPPEEERGTPEGACSVGHEGCVDVPMPAKGAPEQVCGAA~~~DGQLLLRL    1501  
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Figure 2.3. Sequence alignment of human and mouse PLC-η2 with human 
PLC-η1. 
Both human and mouse protein sequences of PLC-η2 (accession number: human, 
mouse) were aligned with those of PLC-η1 (accession number: NM_014996, 
NM_183191).  Conserved residues were highlighted in black, and similar residues 
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were highlighted in gray.  Domains of PLC-η2 were boxed and labeled.  Each exon 
border was marked with a caret (^). 
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Figure 2.4. Diagram of splice variants of mouse PLC-η2 at the carboxyl 
terminus.  
A. Mouse PLC-η2 carboxyl terminal exon-intron structure and predicted splice 
variants.  Three alternative splice forms occur at exon 21 (21a, 21b, or 21c).  The 
absence or presence of exon 22 also represents a splicing event.  The sizes of the 
cDNA sequence of each exon are indicated, and five predicted splice variants and 
their alternative use of exons are graphically illustrated.  In-frame stop codons are 
marked using asterisks (*).  The solid horizontal bars represent individual exon.  
The hashed horizontal bar represents the intron between exon 22 and exon 23.  B. 
List of amino acid sequence encoded by each exon (exon 21 through exon 23). 
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Figure 2.5. RT-PCR analysis of the carboxyl terminus of PLC-η2 in mouse 
tissues. 
The RT-PCR reactions were carried out as described in Methods.  The DNA ladder 
consists of 13 double-stranded, blunt-end fragments with sizes of 250/253, 500, 750, 
1,000, 1,500, 2,000, 2,500, 3,000, 4,000, 5,000, 6,000, 8,000 and 10,000 base pairs.  
RT-PCR of RNA from mouse eye (lane 1 and 2) resulted in amplification of the 
following specific cDNA fragments: 463 bp and 971 bp using 21S/23AS primer pair, 
179 bp and 687 bp using 21S/22AS, 332 bp using 22S/23AS, 187 bp using 
23S/23AS, 945 bp using 21S/21cAS, and 411bp using 21cS/23AS.  RT-PCR of RNA 
from mouse brain (lane 3 and 4) resulted in amplification of the following specific 
cDNA fragments: 971 bp using 21S/23AS, 687 bp using 21S/22AS, 332 bp using 
22S/23AS, 187 bp using 23S/23AS, 945 bp using 21S/21cAS, and 411bp using 
21cS/23AS.  RT-PCR of RNA from mouse lung (lane 5 and 6) resulted in 
amplification of 463 bp using 21S/23AS and 187 bp using 23S/23AS.  Each of the 
above PCR products was sequenced and confirmed to encode carboxyl terminal 
sequence of PLC-η2. 
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Figure 2.6. Expression of native human PLC-η2 in 1321N1 human astrocytoma 
cells. 
Endogenous expression of human PLC-η2 was assessed in whole cell lysates and 
soluble fractions prepared from 1321N1 human astrocytoma cells.  Immunoblots 
were developed using PLC-η2 antibody in the presence or absence of specific 
peptide as described in Methods.  Lysate from COS-7 cells expressing PLC-η2(2-23) 
was used as positive control. 
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Figure 2.7. PLC-η2 is an active phospholipase C enzyme. 
A. Quantification of phospholipase activity at various protein concentrations.  
COS-7 cells transiently expressing PLC-β2 or PLC-η2 (1-23, 1’-23 or 2-23) were 
lysed and the soluble fraction was obtained to test the lipase activity of each PLC 
directly in the presence of substrate [3H]PtdIns-4P and 0.5% cholate as indicated in 
Methods.  The results are presented as mean ± S.E.M. of triplicate determinations.  
B. Quantification of phospholipase activity at various cholate concentrations.  
Samples were prepared as in A, and activity was measured with 200 μg of COS-7 
lysate expressing the indicated PLC enzyme and the indicated concentration of 
cholate. 
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Figure 2.8. Screen of potential G protein activators of PLC-η2. 
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PLC-η2(2-23) was coexpressed with either wild-type or GTPase-deficient mutants of 
various Gα-subunits (A) or Ras superfamily GTPases (B) and [3H]inositol phosphate 
accumulation was measured as described in Methods.  PLC-β1, PLC-β2, or PLC-ε 
was coexpressed with certain G proteins as positive controls.  The results are 
presented as mean ± S.E.M. of triplicate determinations and are representative of 
results from two separate experiments. 
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Figure 2.9. Gβγ dimer promotes activation of PLC-η2. 
The indicated amount of expression vector for PLC-η2(2-23) (left panel) or PLC-ε 
(right panel) was co-transfected with 30 ng of Gβ1 and 30 ng of Gγ2 in COS-7 cells.  
[3H]Inositol phosphate accumulation was quantified as described in Methods.  Data 
are presented as mean ± S.E.M. of triplicate determinations and are representative of 
results from at least five separate experiments.  Inset, the level of PLC-η2 in COS-7 
cells co-expressed with the indicated amounts of Gβ1 and Gγ2 DNA was assessed in 
immunoblots using anti-His antibody. 
CHAPTER 3 
ACTIVATION OF HUMAN PHOSPHOLIPASE C ETA2 BY Gβγ 
 
3.1 Abstract 
 The phospholipase C-η (PLC-η) subfamily of PLC isozymes was recently 
identified, and PLC-η2 was shown to be activated by Gβ1γ2 after transient expression 
in COS-7 cells (Zhou et al. Biochem. J. 391:667-676, 2005).  To define the 
enzymatic properties of PLC-η2 and its potential direct activation by Gβ1γ2, a 
construct of PLC-η2 encompassing the canonical domains of a phospholipase C (PH 
domain through C2 domain) was purified to homogeneity after expression from a 
baculovirus in insect cells and assayed after reconstitution with substrate-containing 
phospholipid vesicles.  Purified PLC-η2 hydrolyzed phosphatidylinositol 
4,5-bisphosphate with an apparent Km of 9.4 μM and Vmax of 5 μmol/min/mg of protein, 
similar to activities previously observed with purified PLC-β or PLC-ε isozymes.  
Moreover, Gβ1γ2 stimulated the phospholipase activity of PLC-η2 in a concentration 
dependent manner similar to that observed with purified PLC-β2.  Activation was 
dependent on the presence of free Gβ1γ2 since its sequestration in the presence of 
Gαi1 or GRK2-ct reversed Gβ1γ2-promoted activation.  The PH domain of PLC-η2 is 
not required for Gβ1γ2-mediated regulation since a purified fragment encompassing 
the EF-hand through C2 domains but lacking the PH domain nonetheless was 
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activated by Gβ1γ2.  Taken together these studies illustrate that PLC-η2 is a direct 
downstream effector of Gβγ and therefore, of receptor-activated heterotrimeric G 
proteins. 
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3.2 Introduction 
 Physiological responses to a variety of extracellular stimuli result from 
phospholipase C (PLC)-catalyzed conversion of the minor membrane phospholipid 
PtdIns(4,5)P2 into the Ca2+-mobilizing second messenger, Ins(1,4,5)P3, and the 
protein kinase C-activating second messenger, diacylglycerol (47;203).  Membrane 
inositol lipids specifically bind to conserved PH, FYVE, PX and other domains found 
in key proteins in a broad range of signaling pathways (204;205).  Thus, by altering 
the ratio of membrane phosphoinositides, PLC isozymes also affect membrane 
association and activity of many signaling proteins. 
 A large family of PLC isozymes exists that includes six subfamilies of PLC (PLC-β, 
-γ, -δ, -ζ, -ε and -η) and a total of thirteen members (77).  All PLC isozymes contain 
canonical PH, EF-hand, catalytic TIM barrel and C2 domains, with the exception of 
sperm-specific PLC-ζ (185), which lacks a PH domain.  PLC-δ isozymes are broadly 
distributed, but description of their mechanism of regulation remains elusive (77).  
PLC-γ isozymes contain SH2 and SH3 (Src homology 2 and 3) domains, and are 
regulated by receptor and non-receptor tyrosine kinases (77;121-123;208).  PLC-γ2 
also was shown recently to be regulated by Rac GTPases (138).  PLC-β isozymes 
are elaborated with a helical C-terminus (140), and are activated directly by Gα 
subunits of the Gq family of heterotrimeric G-proteins (141-143).  Gβγ dimers 
released from heterotrimeric G-proteins of the Gi family also activate PLC-β2 and 
PLC-β3 (23;144;145).  Rac GTPases bind to the PH domain and activate PLC-β2 
(146;147), and a crystal structure of Rac in GTP-dependent complex with PLC-β2 
has provided new insight into the molecular mechanism of G protein-mediated 
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regulation of PLC-β isozymes (148).  PLC-ε contains a CDC25 guanine nucleotide 
exchange factor domain at its amino terminus and two tandem RA domains at its 
C-terminus.  Ras and Rho GTPases bind to the RA domains and the catalytic core, 
respectively, and directly regulate the activity of PLC-ε by distinct mechanisms 
(173-177;212).  
 Four research groups recently reported identification of a pair of PLC isozymes, 
PLC-η1 and PLC-η2 (82-85).  The PLC-η isozymes contain a long C-terminus 
containing a class II PDZ-binding motif.  Human PLC-η2 was shown to be activated 
by Gβ1γ2 in vivo (85), and its mouse homologue was hypothesized to be involved in 
neuronal function in development (83).  We now have determined that 
Gβ1γ2-dependent activation of PLC-η2 is retained by a truncated form of the isozyme 
encompassing the canonical catalytic core of the enzyme.  Moreover, with the goal 
of determining whether PLC-η2 is subject to direct regulation by G protein subunits, 
we purified two different PLC-η2 constructs, and we illustrate that PLC-η2 is directly 
activated by Gβ1γ2 in a manner that depends on the presence of free G protein dimer.  
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3.3 Experimental procedures 
Materials 
Inositol-free medium was purchased from ICN Biochemicals (Costa Mesa, CA, 
U.S.A.).  [Inositol-2-3H]-Phosphatidylinositol-4,5-bisphosphate substrate was 
purchased from Perkin Elmer (Boston, MA), and brain 
L-α-phosphatidylinositol-4,5-bisphosphate and bovine liver 
L-α-phosphatidylethanolamine were purchased from Avanti Polar Lipids (Alabaster, 
AL).  Protease inhibitor tablets were obtained from Roche Applied Science (Madison, 
WI).  All other reagents were from sources previously reported (85). 
DNA sequence of human PLC-η2 corresponding to amino acids 42 to 1416 
[PLC-η2(2-23)] or corresponding to amino acids 42 to 872 [PLC-η2(PH-C2)] were 
cloned into pcDNA3.1 vector at the 5’ EcoRI and 3’ XbaI sites.  
Purification of PLC-η2 
 DNA sequence of human PLC-η2 corresponding to amino acids 42 to 872 
[PLC-η2(PH-C2)] or corresponding to amino acids 168 to 872 [PLC-η2(EF-C2)] were 
subcloned into pFastbac HTa vector at the 5’ EcoRI and 3’ XbaI sites with a 
hexahistidine (6xHis) tag and TEV (tobacco etch virus) cleavage site engineered at 
the amino-terminus.  Conditions for expression and subsequent purification of these 
two different forms of PLC-η2 were essentially identical.  Thus, recombinant 
baculovirus for PLC-η2(PH-C2) or PLC-η2(EF-C2) was used to infect HighFive insect 
cells at a multiplicity of infection (MOI) of 1.  After 48 h of incubation at 27º C, cells 
were harvested by low speed centrifugation at 700g for 15 min at 4º C and 
resuspended in buffer A (20 mM Hepes, pH 8, 400 mM NaCl, 1 mM CaCl2, 15 mM 
 91
imidazole, 10 mM 2-mercaptoethanol, 5% glycerol, and protease inhibitor tablet 
(Roche)).  Cells were then lysed with an EmulsiFlex C5 cell homogenizer (Avestin), 
and the lysate was subjected to centrifugation at 100,000g for 55 min.  The clarified 
supernatant was filtered through a 0.2 micron bottle top filter (Fisher Scientific).  
Ni-NTA resin (1 ml resin per liter culture) was added to the filtered supernatant, which 
was directly poured into a chromatography column.  The flow-through was collected 
and passed over the column two more times to increase protein binding with Ni resin.  
The column was then washed with 20 bed-volumes of buffer A.  The 6xHis tagged 
PLC-η2 was eluted with 2 bed-volumes of buffer B (buffer A + 150 mM imidazole).  
The PLC-containing fractions of the eluant were combined and loaded onto a 
Superdex 200 gel filtration column and subjected to FPLC separation.  Samples 
were eluted in buffer C (20 mM Hepes, pH 8, 150 mM NaCl, 1 mM CaCl2, 10 mM 
2-mercaptoethanol and 10% glycerol). 
Purification of recombinant Gβ1γ2, Gαi1, and GRK-CT 
Recombinant baculoviruses encoding 6His-Gαi1, Gβ1 and Gγ2 were used to 
co-infect HighFive cells at an MOI of 0.7(6His-Gαi1):0.35(Gβ1):0.26(Gγ2).  After 48 h 
of incubation at 27º C, cells were harvested by low speed centrifugation and 
resuspended in buffer I (20 mM Hepes, pH 8, 100 mM NaCl, 10 mM EDTA, 2 mM 
MgCl2, 10 mM 2-mercaptoethanol, 10 μM GDP and protease inhibitor tablet).  Cells 
were then lysed with an EmulsiFlex C5 cell homogenizer (Avestin), and the lysate 
was subjected to centrifugation at 100,000g for 55 min.  The particulate membrane 
fraction was resuspended in buffer II (20 mM Hepes, pH 8, 100 mM NaCl, 1 mM 
MgCl2, 10 mM 2-mercaptoethanol, 10 μM GDP and protease inhibitor tablet), 
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dounce-homogenized by 25 strokes, and solubilized with 1% sodium cholate to 
extract membrane-bound proteins at 4º C for 1 h on a stir plate.  The membrane 
extract was centrifuged at 100,000g for 55 min.  The clarified supernatant was 
batch-loaded with Ni-NTA resin at 4º C for 3 h and poured over a column.  The 
flow-through was collected, and the Ni resin was washed with 50 ml (25 bed-volumes) 
of buffer III (20 mM Hepes, pH 8, 300 mM NaCl, 0.5% C12E10, 1 mM MgCl2, 10 mM 
2-mercaptoethanol, 10 μM GDP and 10 mM imidazole) followed by 10 ml (5 
bed-volumes) of buffer IV (20 mM Hepes, pH 8, 100 mM NaCl, 0.2% sodium cholate, 
10 μM GDP, 10 mM 2-mercaptoethanol, 10 mM imidazole and 1 mM MgCl2).  The 
column was brought to room temperature for 15 min and further washed three times 
with 2 ml (1 bed-volume) of buffer IV (warmed to 30º C).  Gβ1γ2 dimer was then 
eluted with six separate additions of 2 ml (1 bed-volume) of buffer V (20 mM Hepes, 
pH 8, 50 mM NaCl, 1% sodium cholate, 10 μM GDP, 10 mM 2-mercaptoethanol, 10 
mM imidazole, 50 mM MgCl2, 10 mM NaF, 30 μM AlCl3 and protease inhibitor tablet, 
warmed to 30ºC), and 6H-Gαi1 eluted with six separate additions of 2 ml (1 
bed-volume) of buffer F (20 mM Hepes, pH 8, 100 mM NaCl, 1% sodium cholate, 10 
μM GDP, 10 mM 2-mercaptoethanol, 150 mM imidazole, 1 mM MgCl2 and protease 
inhibitor tablet, warmed to 30ºC).  Two fractions of Gβ1γ2-containing eluant were 
combined and concentrated using a VIVASPIN6 10,000 MWCO column in a swing 
bucket rotor centrifuged at 2,500 cpm according to manufacturer’s protocol.  The 
concentrated protein was passed over a G-25 gel filtration column to exchange the 
sample into buffer VI (20 mM Hepes, pH 8, 100 mM NaCl, 0.7% sodium cholate and 
10 mM 2-mercaptoethanol).  The desalted material was then concentrated as above.  
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Protein concentrations were determined by comparison to a BSA standard on a 
commassie-stained SDS-PAGE gel.  Gαi1 was purified in the same fashion as above 
except infections were with baculoviruses for Gαi1 lacking a 6xHis tag and with Gγ2 
containing a 6xHis tag.  [35S]GTPγS binding assays were carried out to confirm that 
the purified Gαi1 stoichiometrically bound GTP, and therefore, was fully active. 
A bacterial expression plasmid (pER28a) encoding the PH domain of G protein 
coupled receptor kinase 2 (GRK2-CT; residues 548-641 with six C-terminal histidines) 
was a generous gift from A. Bohm.  GRK2-CT was purified as we previously 
described (147).  
In vitro PLC assay 
PLC activity and its potential regulation by Gβ1γ2 was quantified using 
phosphatidylethanolamine (PE)- and PtdIns(4,5)P2-containing vesicles as previously 
described in detail (213).  Briefly, recombinant proteins were reconstituted with lipid 
vesicles containing 50 μM PtdIns(4,5)P2 (unless otherwise indicated; Avanti Polar 
Lipids), 500 μM PE (Avanti Polar Lipids), and ~8,000 cpm of [3H]PtdIns(4,5)P2 (Perkin 
Elmer) per assay.  Final buffer conditions were 20 mM HEPES, pH 7.2, 70 mM KCl, 
3 mM EGTA, 2 mM dithiothreitol, 0.16 mg/ml fatty acid-free bovine serum albumin, 
and 10 μM free Ca2+ in a final volume of 60 μl.  All reactions were carried out at 32º 
C for 10 min (unless otherwise indicated) and were terminated by the addition of 200 
μl of 10% trichloroacetic acid and 100 μl of 10 mg/ml fatty acid-free bovine serum 
albumin.  Centrifugation of the reaction mixture separated aqueous [3H]Ins(1,4,5)P3 
from precipitated [3H]PtdIns(4,5)P2, and soluble [3H]Ins(1,4,5)P3 was quantified by 
liquid scintillation counting.  
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For experiments determining the effects of Gβ1γ2 on phospholipase C activity, 
purified Gβ1γ2 dimer in cholate detergent was combined with phospholipid vesicles, 
therein diluting cholate to concentrations well below its critical micellar concentration.  
For experiments determining the effects of Gαi1 on the capacity of Gβ1γ2 to activate 
PLC, 10 μl of purified Gβ1γ2 and Gαi1 were combined in the presence of 10 μM GDP 
on ice for 20 min prior to lipid vesicle reconstitution.  For experiments determining 
the effects of GRK2-ct on the Gβ1γ2-mediated activation of PLC, 10 μl of purified 
Gβ1γ2 and GRK2-ct were combined on ice for 20 min prior to lipid vesicle 
reconstitution. 
Quantification of PLC activity in COS-7 cells 
COS-7 cells were seeded in 12-well plates at a density of 70,000 cells/well and 
maintained in DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% 
(v/v) fetal bovine serum at 37º C in an atmosphere of 90% air/10% CO2.  PLC-β2, 
PLC-η2(2-23), or PLC-η2(PH-C2) plasmid DNA was transfected into COS-7 cells in 
the absence or presence of expression vectors for Gβ and Gγ subunits using Fugene 
6 (Roche) transfection reagent according to the manufacturer’s protocol.  The 
medium was changed to inositol-free DMEM containing 1 μCi of [3H]inositol/well 24 h 
after transfection.  After an additional 18 h incubation, [3H]inositol phosphate 
accumulation was initiated by addition of LiCl to a final concentration of 50 mM.  The 
reaction was stopped after 60 min by aspiration of the medium and the addition of 50 
mM ice-cold formic acid.  [3H]Inositol phosphates were quantified as described 
previously (209). 
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3.4 Results 
Activation of PLC-η2 by Gβ1γ2 in COS-7 cells—Our previous studies 
quantifying [3H]inositol phosphate accumulation in COS-7 cells after transient 
expression of proteins from mammalian expression vectors revealed that Gβ1γ2 
promotes activation of essentially full length (exons 2-23; Figure 3.1A) human 
PLC-η2.  With the goal of determining whether regulation of PLC-η2 by Gβγ occurs 
through a direct mechanism, we initiated studies to purify PLC-η2 and examine 
potential regulation of enzymatic activity by purified Gβ1γ2.  Multiple attempts to 
purify full-length PLC-η2 after expression from a baculovirus in insect cells yielded 
insufficient amounts of purified protein, and two major degradation products of 
PLC-η2 were observed.  Therefore, we considered whether regulation by Gβ1γ2 was 
retained in a truncated form(s) of PLC-η2, and if so, whether this PLC-η2 protein 
could be purified with adequate yield.  A mammalian expression vector was 
generated for a truncated version of PLC-η2 that encompassed the PH domain 
through C2 domain (amino acids 42-872; Figure 3.1A).  This truncated PLC-η2 was 
expressed in COS-7 cells and its potential regulation by Gβ1γ2 was examined by 
cotransfection of cells with expression vectors for Gβ1 and Gγ2.  As we previously 
reported (85), Gβ1γ2-dependent increases in [3H]inositol phosphate accumulation 
were observed in COS-7 cells expressing PLC-η2(2-23) (Figure 3.1B).  Moreover, 
the extent of activation of PLC-η2(PH-C2) by Gβ1γ2 was similar to that of 
PLC-η2(2-23), but less than the activity observed when Gβ1γ2 was coexpressed with 
PLC-β2. 
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The possibility that Gβγ dimers in addition to Gβ1γ2 activate PLC-η2 also was 
examined in COS-7 cells transfected with essentially maximal amounts of DNA for 
expression of various Gβγ dimers from Gβ1-5 in complex with Gγ2.  Immunoblots 
illustrated similar levels of expression of all five different Gβxγ2-containing dimers 
tested, although the level of expression was reproducibly slightly higher with Gβ1γ2 
(data not shown).  The largest activation of both PLC-η2 and PLC-β2 was observed 
with Gβ1γ2 (Figure 3.1C), and the pattern of relative activities observed with the other 
Gβγ dimers was similar for PLC-η2 versus PLC-β2.  Thus, Gβ2γ2 and Gβ4γ2 activated 
both PLC isozymes, whereas no reproducible activation was observed with Gβ3γ2.  
Gβ5γ2 slightly activated PLC-β2,  but no reproducible activation of PLC-η2 was 
observed with this G protein dimer. 
Purification of PLC-η2(PH-C2)—Given that Gβ1γ2-mediated regulation of 
PLC-η2 was retained in COS-7 cells in studies with a truncated version of this 
isozyme, we constructed a recombinant baculovirus for expression of a protein that 
encompasses the PH through the C2 domain (amino acids 42-872; Figure 3.1A) of 
PLC-η2.  PLC-η2(PH-C2) was expressed to high levels without observable 
degradation products and was readily purified after overexpression in HighFive insect 
cells as described in “Experimental Procedures.”  Yields of purified protein averaged 
5 mg per liter of infected cells with approximately 90% purity obtained in a single 
Ni-NTA affinity purification step.  Analyses of the purified protein by size exclusion 
chromatography revealed that greater than 50% existed as soluble aggregates under 
the conditions of these studies.  Therefore, a Superdex 200 size-exclusion 
chromatography step was included, and the final purified isozyme migrated as a 
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monomer of the predicted size (approx. 100 KDa).  The purified isozyme was 
essentially homogeneous as assessed by coomassie staining of SDS-PAGE gels 
(Figure 3.2A); assessment with a PLC-η2 specific antibody also indicated that little or 
no proteolysis of PLC-η2(PH-C2) occurred (data not shown). 
Enzymatic Properties of Purified PLC-η2(PH-C2)—Purified PLC-η2(PH-C2) 
exhibited marked phospholipase C activity in assays using mixed detergent 
phospholipid micelles containing 50 μM [3H]PtdIns(4,5)P2 as substrate.  
Phosphoinositide hydrolysis was linear for at least 10 min under the assay conditions 
(Figure 3.2B) and was proportional to the amount of purified enzyme used over a 
wide range of concentrations (data not shown). The enzymatic activity (~8 
μmol/min/mg of protein) observed with 50 μM substrate was similar to activities we 
previously observed with purified PLC-β and PLC-ε isozymes quantified under similar 
conditions.  Kinetic analysis of PLC-η2(PH-C2) also was performed using PE- and 
[3H]PtdIns(4,5)P2-containing vesicles presented at various concentrations in the bulk 
medium.  Assays carried out under these conditions with PLC-η2(PH-C2) revealed 
a Vmax of 5 μmol/min/mg and a Km for PtdIns(4,5)P2 of 9.4 μM (Figure 3.2C). 
Activation of Recombinant PLC-η2 by Gβ1γ2—Gβ1γ2 directly activates PLC-β2 
and PLC-β3, and although Gβ1γ2 also stimulates PLC-ε-dependent increases in 
inositol phosphate accumulation in intact cells (176), we have been unable to observe 
direct activation of PLC-ε in in vitro reconstitution assays.  To determine whether 
Gβ1γ2 directly activates PLC-η2, Gβ1γ2 was expressed from recombinant 
baculoviruses in insect cells, purified to near homogeneity from detergent-extracted 
membranes (Figure 3.3A inset), and reconstituted in substrate-containing 
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phospholipid vesicles.  The capacity of 500 nM Gβ1γ2 to activate PLCη2(PH-C2) 
was compared to its capacity to activate PLC-β2(PH-C2).  The basal level of 
PtdIns(4,5)P2 hydrolysis was consistently higher in the presence of PLC-η2(PH-C2) 
compared to PLC-β2 (PH-C2), suggesting that PLC-η2 may exhibit less autoinhibition 
(or basally interact with substrate-containing membranes more effectively) than 
PLC-β2.  Co-reconstitution with Gβ1γ2 resulted in increased activities of both 
isozymes although the fold stimulation was greater for PLC-β2(PH-C2) than for 
PLC-η2(PH-C2) (Figure 3.3A). 
Gβ1γ2 was reconstituted in phospholipid vesicles over a wide range of 
concentrations (Figure 3.3B), and concentration of Gβ1γ2-dependent increases in 
PtdIns(4,5)P2 hydrolysis were observed with both purified PLC-η2(PH-C2) and 
purified PLC-β2(PH-C2).  Half-maximal activation occurred at a concentration of 
Gβ1γ2 of 557 ± 190 nM (n=3 experiments) for PLC-η2(PH-C2) and 133 ± 50 nM (n=3 
experiments) for PLC-β2(PH-C2).  
To establish that the effects observed with Gβ1γ2 represented effector activation 
that depended on the presence of free Gβγ dimer, the natural binding partner of Gβγ, 
Gαi1, was purified after expression in HighFive cells (Figure 3.4A Inset), and 
reconstituted in substrate-containing phospholipid vesicles with purified Gβ1γ2 in the 
presence of GDP.  As illustrated in Figure 3.4A, the Gβ1γ2-dependent stimulation of 
phospholipase activity of PLC-η2(PH-C2) was inhibited to basal levels in the 
presence of GDP-bound Gαi1, suggesting that the activation of PLC-η2(PH-C2) was 
indeed Gβγ-specific.  Similar effects of Gαi1 on Gβ1γ2-stimulated PLC-β2 activity 
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were observed.  Gαi1 was further reconstituted over a wide range of concentrations 
in phospholipid vesicles with a fixed amount of Gβ1γ2.  The addition of Gαi1 inhibited 
Gβ1γ2 activation of both PLC-η2(PH-C2) and PLC-β2(PH-C2) in a 
concentration-dependent manner (Figure 3.4B).  The curve for Gαi1-mediated 
reversal of activation of PLC-η2(PH-C2) was shifted to the left compared to that for 
inhibition of PLC-β2(PH-C2) activation, which was consistent with the fact that higher 
concentrations of Gβ1γ2 were necessary for activation of PLC-η2(PH-C2) compared 
to PLC-β2(PH-C2). 
To further confirm the selectivity of Gβγ activation, GRK2-ct (amino acids 495-689) 
was employed in the reconstitution assay as another protein that binds Gβγ, and 
therein, potentially inhibits activation of effector enzymes that is dependent on the 
presence of free Gβγ.  As shown in Figure 3.5, the addition of GRK2-ct reversed the 
activation of both PLC-η2 and PLC-β2 by Gβ1γ2 to basal levels, and it did so in a 
concentration-dependent manner.  Thus, GRK2-ct sequesters free Gβγ, and 
therefore, Gβγ-mediated activation of PLC-η2 is lost. 
Previous studies with PLC-β2 have implicated the PH domain in activation of this 
isozyme by Gβγ (146-148).  Therefore, a construct of PLC-η2 that eliminates this 
conserved domain and encompasses the EF-hand repeats through the C2 domain 
(amino acids 168-872; Figure 3.1A) was produced, and PLC-η2(EF-C2) was purified 
to homogeneity (Figure 3.2A) as described in “Materials and Methods”.  Kinetic 
analyses using addition of different amounts of PtdIns(4,5)P2 substrate in the bulk 
medium revealed that the lipase activity (Vmax = 7.8 μmol/min/mg) of purified 
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monomeric PLC-η2(EF-C2) was similar to that of PLC-η2(PH-C2), although the 
observed Km (approximately 50 μM) for PtdIns(4,5)P2 was higher (data not shown).  
As illustrated in Figure 3.6, Gβ1γ2 also activated this PLC-η2 lacking the PH domain, 
and therefore, we conclude that activation by this G protein heterodimer occurs at 
least in part through interaction with the catalytic core of the isozyme. 
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3.5 Discussion 
 The work described here illustrates direct, concentration-dependent stimulation 
of purified PLC-η2 in phospholipid vesicles reconstituted with purified Gβ1γ2.  Thus, 
we have identified a novel effector of Gβγ, and implicated this isozyme in signaling 
responses downstream of heterotrimeric G-protein-coupled receptors. 
The involvement of multiple G proteins in receptor-promoted regulation of inositol 
lipid signaling was first realized in studies of the PLC-β isozymes.  Gα subunits of 
the Gq family initially were shown to mediate guanine nucleotide-dependent activation 
(140-143), but subsequent studies revealed that PLC-β2 and PLC-β3 also are 
activated by Gβγ subunits of heterotrimeric G proteins (23;144;145).  The apparent 
complexity of G protein-dependent regulation of inositol lipid signaling was further 
increased by realization that the small GTPase Rac binds and activates PLC-β2 
(146-148).  Moreover, the most divergent member of the PLC isozyme family, PLC-ε, 
was initially discovered as a Ras-binding protein in C. elegans, and the mammalian 
isoform is dually activated by Ras (173-175) and Rho (177;212) through direct 
binding of these GTPases to two different regions of the isozyme.  Although PLC-γ 
isozymes are activated by phosphorylation by receptor and other tyrosine kinases, 
PLCγ2 is additionally activated by Rac (138).  Our transient expression studies in 
intact COS-7 cells originally implicated activation of PLC-η2 by Gβγ subunits, and the 
results presented here confirm the idea that this novel PLC isozyme exhibits the 
characteristics of a direct effector of Gβγ. 
We previously screened all of the heterotrimeric Gα subunits and 17 different 
Ras-superfamily GTPases for potential stimulation of PLC-η2 after coexpression in 
 102
COS-7 cells, and only Gβγ was identified as an activator of the isozyme.  Additional 
comprehensive analyses are needed, but within the limitations of our screens to date 
PLC-η2 is the only PLC isozyme that is solely regulated by Gβγ.  Although Gβ1γ2 
was the only dimer tested as a purified protein, co-transfection studies indicate that 
the relative effects of Gβγ subunits of various subunit composition are very similar for 
activation of PLC-η2 versus activation of PLC-β2.  Although Nakahara and 
coworkers reported that mouse PLC-η2 is a neuron-specific isozyme (82), our 
studies with human PLC-η2 illustrated that it is expressed both in brain and 
peripheral tissues suggesting that it may serve an important role in G 
protein-mediated signaling in multiple tissues.  Given the similarity in sequence 
between PLC-η2 and PLC-η1, we also tested whether Gβ1γ2 activates both members 
of this subfamily of PLC isozymes.  In our preliminary transfection experiments in 
COS-7 cells, we did not observe Gβγ-dependent activation of PLC-η1 within the 
limitations of transfection experiments (data not shown).  Whether this PLC isozyme 
is regulated by other small GTPases or heterotrimeric G protein subunits remains 
unreported. 
The last three exons of the PLC-η2 gene are alternatively spliced in both mice 
and humans to produce at least four splice variants containing markedly variable C 
terminal domains beyond the C2 domain (85).  The physiological relevance of these 
different forms of PLC-η2 is not yet known, but as illustrated here removal of the 
C-terminal 545 amino acids does not demonstrably affect its regulation by Gβ1γ2.  
Previous studies have illustrated that Gβγ interacts with multiple sites in PLC-β2, and 
both the catalytic and PH domains have been implicated for Gβγ-dependent 
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activation of the isozyme (146;163-165).  A construct of PLC-η2 that encompassed 
the PH through C2 domain retained activation by Gβ1γ2 both in vivo and in vitro, but 
observation of similar levels of activation of a fragment of PLC-η2 lacking the PH 
domain illustrates that in contrast to PLC-β2, the PH domain of PLC-η2 is relatively 
unimportant in Gβ1γ2-mediated regulation.  Alternatively, Nakahara and coworkers 
(83) illustrated that PLC-η2 is predominantly associated with the plasma membrane 
in mouse brain and reported that the PH domain is necessary for membrane 
localization. 
The mechanism whereby Gβγ activates PLC-β2, and now PLC-η2, also remains 
to be defined.  Activation could follow from simple Gβγ-dependent recruitment to 
phosphoinositide substrate-containing membranes or activation may involve G 
protein-promoted conformational changes in the catalytic core of the enzyme.  
Mechanistic insight into the activation of PLC isozymes has accrued from our recent 
structural and biochemical studies illustrating that PLC-β2, and ostensibly PLC-δ and 
PLC-ε, are autoinhibited by the unstructured X-Y linker region of the isozymes [(148); 
Hicks et al. 2007, unpublished].  These studies strongly suggest that the active 
site-occluding X-Y-linker moves as a consequence of dense negative charges in the 
linker encountering negatively charged membrane surfaces; autoinhibition is relieved 
and access to PtdIns(4,5)P2 substrate is promoted.  Thus, our structures of 
holo-PLC-β2 and PLC-β2 in GTP-dependent complex with Rac1 illustrate that 
Rac-mediated activation of PLC-β2 follows from simple recruitment of the enzyme to 
membrane surfaces.  In contrast, our biochemical studies of Gβγ-dependent 
activation of PLC-β2 suggest a more complex mode of regulation involving the 
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catalytic core of the enzyme, and therefore the mechanism(s) whereby Gβγ activates 
PLC-β2 and other PLC isozymes remains unclear.  The Gβγ-binding interface has 
not yet been structurally identified in any PLC isozyme, and it will be important to 
establish unambiguously whether Gβγ binds to PLC-η2 and PLC-β2 through similar 
or different determinants. 
A notable difference between PLC-η2 and PLC-β2 is that the overall charge of 
PLC-η2 is much more positive than PLC-β2, and the X-Y linker of PLC-η2 is 
essentially devoid of sequence containing dense negative charge and overall is 
positively charged.  Thus, we anticipate that PLC-η2 exhibits less autoinhibition and 
greater electrostatic force-dependent attraction to phosphoinositide 
substrate-containing membrane surfaces.  Such properties likely explain the high 
basal activity of PLC-η2, and given these differences in PLC-β2 and PLC-η2, it is 
perhaps not surprising that the fold-activation of PLC-β2 by Gβ1γ2 was greater than 
that observed with PLC-η2.  Nomikos and coworkers (186) recently concluded that a 
dense positive region in the X/Y linker of PLC-ζ also is important for membrane 
association and activity of this sperm specific isozyme. 
In conclusion, we have demonstrated that Gβ1γ2 directly activates PLC-η2.  
Future experiments will delineate the region of Gβ1γ2 interaction and reveal the 
mechanism of activation.  The physiological role of Gβ1γ2-mediated activation of 
PLC-η2 is under investigation. 
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Figure 3.1.  Activation of PLC-η2 by G-protein Gβγ dimers. 
A, schematic representation of PLC-η2(2-23) (residues 42-1416, top), 
PLC-η2(PH-C2) (residues 42-872, middle) and PLC-η2(EF-C2) (residues 168-872, 
bottom).  PLC-η2(2-23) (exon 2-23) is an alternative splice variant that lacks the first 
exon (41 amino acids) of human PLC-η2 (accession number: DQ176850) (Zhou et al. 
2005).  PLC-η2(PH-C2) lacks the C-terminal 545 amino acids of PLC-η2(2-23); 
PLC-η2(EF-C2) additionally lacks the N-terminal PH domain.  PLC-η2(2-23), or 
PLC-η2(PH-C2), was co-expressed with Gβ1γ2 (B) or Gβ1-5γ2 (C), and [3H]inositol 
phosphate accumulation was measured as described under “Experimental 
Procedures.”  PLC-β2 was co-expressed with Gβγ as a positive control.  The 
results are presented as means ± S.E.M. for triplicate determinations, and are 
representative of results from two to three separate experiments. 
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Figure 3.2.  Characterization of the phospholipase activity of PLC-η2(PH-C2). 
A, coomassie-stained SDS-PAGE gel of purified PLC-η2(PH-C2) and 
PLC-η2(EF-C2).  B, time course of PtdIns(4,5)P2 hydrolysis in the presence of 5 ng 
PLC-η2(PH-C2) was tested.  C, the lipase activity of 5 ng PLC-η2(PH-C2) was 
assayed with increasing concentrations of PtdIns(4,5)P2 substrate.  The data shown 
are the mean ± S.E. of three individual experiments. 
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Figure 3.3.  Activation of PLC-η2(PH-C2) by purified Gβ1γ2. 
Recombinant Gβ1γ2 at 500 nM (A) or at various concentrations (B) was reconstituted 
in phospholipid vesicles as described under “Experimental Procedures.”  
PLC-η2(PH-C2) or PLC-β2(PH-C2) was added and the assay was performed at 32º 
C for 10 min.  The data from multiple experiments were transformed and pooled by 
subtracting basal activities (2-4 pmol/min/ng for PLC-η2 and 0.5-1 pmol/min/ng for 
PLC-β2) from maximal Gβ1γ2-stimulated activities (6-9 pmol/min/ng for PLCη2 and 
12-15 pmol/min/ng) for PLCβ2) to provide values for “maximal activation”.  
Identically calculated values for each concentration of Gβ1γ2 were then divided by the 
values for maximal activation to provide value for “% maximal activation”.  The 
results presented are the mean ± S.E. of at least three separate experiments.  
Inset, Recombinant Gβ1γ2 was purified from detergent-extracted HighFive insect cell 
membranes.  Proteins were resolved by SDS-PAGE and stained with coomassie 
blue. 
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Figure 3.4.  Gαi1-dependent inhibition of Gβ1γ2-promoted activation of 
PLC-η2(PH-C2). 
Recombinant Gαi1 at 2 μM (A) or at various concentrations (B) was reconstituted with 
1 μM Gβ1γ2 in phospholipid vesicles as described under “Experimental Procedures.”  
PLC-η2(PH-C2) (1 ng) or PLC-β2(PH-C2) (5 ng) was added and the assay was 
performed at 32º C for 10 min.  The data from multiple experiments were 
transformed and pooled by subtracting basal activities (2-4 pmol/min/ng for PLC-η2 
and 0.5-1.0 pmol/min/ng for PLC-β2) from activities (6-9 pmol/min/ng for PLCη2 and 
12-15 pmol/min/ng) for PLCβ2) observed in the presence of 1 μM Gβ1γ2 to provide 
values for “maximal activation”.  Identically calculated values were obtained for each 
combination of 1 μM Gβ1γ2 with the indicated concentrations and these values were 
divided by that for “maximal activation” to provide a value for “% maximal activation”.  
The results presented are the mean ± S.E. of at least three separate experiments.  
Inset, Recombinant Gαi1 was purified from detergent-extracted HighFive insect cell 
membranes, resolved by SDS-PAGE and stained with coomassie blue. 
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Figure 3.5.  GRK2-ct-mediated reversal of Gβ1γ2-promoted activation of 
PLC-η2(PH-C2). 
Increasing concentrations of GRK2-ct were reconstituted with 1 μM Gβ1γ2 in 
phospholipid vesicles as described under “Experimental Procedures.”  5 ng 
PLC-η2(PH-C2), or 5 ng PLC-β2(PH-C2) was added and the assay was performed at 
32º C for 10 min.  The data from multiple experiments were transformed and pooled 
by subtracting basal activities (2-4 pmol/min/ng for PLC-η2 and 0.5-1.0 pmol/min/ng 
for PLC-β2) from activities (6-9 pmol/min/ng for PLCη2 and 12-15 pmol/min/ng) for 
PLCβ2) observed in the presence of 1 μM Gβ1γ2 to provide values for “maximal 
activation”.  Identically calculated values were obtained for each combination of 1 
μM Gβ1γ2 with the indicated concentrations and these values were divided by that for 
“maximal activation” to provide a value for “% maximal activation”.  The results 
presented are the mean ± S.E. of at least three separate experiments. 
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Figure 3.6.  Retention of Gβ1γ2-mediated activation in a purified construct of 
PLC-η2 lacking the PH domain. 
Recombinant Gβ1γ2 at 500 nM was reconstituted in phospholipid vesicles with 
PLC-η2(PH-C2) or PLC-η2(EF-C2).  The assay was performed at 32º C for 10 min. 
The results presented are the mean ± S.E. of at least three separate experiments. 
CHAPTER 4 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 My Ph.D. thesis focused on molecular characterization of the newest isozyme of 
the phospholipase C family, PLC-η. Two isoforms of PLC-η exist; PLC-η1 locates on 
human chromosome 3q25.31, and PLC-η2 on human chromosome 1p36.32. Our 
laboratory identified both human PLC-η sequences using the NCBI non-redundant 
database BLAST algorithm against the conserved sequences in the catalytic core of 
a PLC. My researches focused on isolating human PLC-η2 gene, providing some 
insight into its expression in several alternatively spliced forms, and identifying 
possible G-protein regulators of this novel isozyme. 
 Most of the coding sequence of PLC-η2 was constructed from two available ESTs. 
These sequences were confirmed by multiple existing ESTs and mRNAs and also 
partially by PCR with human retina and kidney cDNA. A 5’-RACE PCR was used with 
human retina cDNA as template, and an upstream exon (exon 1), not deduced from 
available EST or mRNA sequences, was identified. This exon was also confirmed 
using a human kidney cDNA library. Genomic analysis indicates that PLC-η2 is 
composed of at least 23 exons and alternative splicing occurs at exons 21, 22, and 
23. Messenger RNA transcripts of at least four splice variants of PLC-η2 (both human 
and mouse) were observed using RT-PCR in retina, brain, lung, and human 1321N1 
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cells and SHSY5Y human neuroblastoma cells. Endogenous protein of one splice 
variant of human PLC-η2 was observed using immunoblot analysis of proteins of 
human 1321N1 astrocytoma cells. 
 Amino acid sequence analysis revealed that PLC-η2 contains all the canonical 
domains of a PLC and a long C-terminal region, within which no obvious domain is 
predicted. However, a class II PDZ-binding motif, LLRL, is present at the C-terminus 
of PLC-η2, which is conserved in mouse PLC-η2 sequences, as well as in both 
human and mouse sequences of PLC-η1. One splice form of PLC-η2, PLC-η2(2-23), 
migrates as a 155 kDa species when expressed in COS-7 cells, and is 
immunoreactive to a PLC-η2-specific antisera that we developed. When 
PLC-η2(2-23) was exogenously expressed in COS-7 cells, we observed a marked 
increase in inositol phosphates accumulation. The soluble fraction of COS-7 cell 
lysates transiently expressing PLC-η2(2-23) exhibited marked phospholipase activity 
in assays with [3H]PtdIns(4)P- or [3H]PtdIns(4,5)P2-containing phospholipid vesicles. 
 To determine whether PLC-η2 is activated by G-proteins, we co-expressed 
PLC-η2 with all Gα subunits (wild-type Gαq, Gα11, Gα14 and Gα15/16, and Gln?Leu 
mutants of all 15 Gα subunits), Gβγ dimer, or 17 Ras-superfamily GTPases in COS-7 
cells and measured inositol phosphates accumulation. No activation of PLC-η2 was 
observed during co-expression with any Gα subunits or Ras GTPases. Although 
activation of PLC-η2(2-23) may occur downstream of certain Gα subunits or Ras 
GTPases, no evidence of such activation was obtained under the conditions our 
assays. However, co-expression of PLC-η2(2-23) with Gβγ resulted in marked 
stimulation of inositol lipid hydrolysis compared with cells expressing PLC-η2(2-23) 
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alone. Expression of soluble PLC-η2(2-23) did not increase as a consequence of Gβγ 
expression, indicating that the increased activity of PLC-η2(2-23) is indeed a result of 
Gβγ-promoted activation. Furthermore, Gβγ activation of PLC-η2 was retained when 
a fragment of PLC-η2 corresponding to PH through C2 domain, PLC-η2(PH-C2), was 
co-expressed with Gβγ in COS-7 cells. These results suggest that Gβγ mediates its 
activation within the canonical domains of PLC-η2. Moreover, the capability of 
various Gβγ dimers (Gβ1-5 in complex with Gγ2) to activate PLC-η2 was examined in 
COS-7 cells. Similar levels of expression of all five different Gβxγ2-containing dimers 
were observed, although the level of expression was reproducibly slightly higher with 
Gβ1γ2. The largest activation of PLC-η2 was observed with Gβ1γ2; Gβ2γ2 and Gβ4γ2 
activated PLC-η2, whereas no reproducible activation was observed with Gβ3γ2 and 
Gβ5γ2. Similar activation pattern was observed for PLC-β2. 
To determine whether Gβγ activation of PLC-η2 was through a direct mechanism, 
both PLC-η2(PH-C2) and Gβγ were expressed from baculoviruses in insect cells and 
purified to homogeneity. Since multiple attempts to purify an essentially full length 
PLC-η2 yielded insufficient amounts of purified protein and major degradation 
products, PLC-η2(PH-C2) was considered and purified with adequate yield. Purified 
PLC-η2(PH-C2) exhibited marked phospholipase C activity in assays using mixed 
detergent phospholipid micelles containing 50 μM [3H]PtdIns(4,5)P2 as substrate. 
Phosphoinositide hydrolysis was linear for at least 10 min and was proportional to the 
amount of purified enzyme used over a wide range of concentrations. An enzymatic 
activity of ~8 μmol/min/mg of protein observed with 50 μM substrate was similar to 
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activities of purified PLC-β and PLC-ε quantified under similar conditions. Kinetic 
analysis of PLC-η2(PH-C2) using PE- and [3H]PtdIns(4,5)P2-containing vesicles 
presented at various concentrations in bulk medium revealed a Vmax of 5 
μmol/min/mg and a Km for PtdIns(4,5)P2 of 9.4 μM.  
In vitro reconstitution of both purified PLC-η2(PH-C2) and Gβ1γ2 in the 
substrate-containing lipid vesicles have reproducibly resulted in a two-three fold 
increase in enzymatic activity of PLC-η2. The fold stimulation was greater for 
PLC-β2(PH-C2) than for PLC-η2(PH-C2). A wide range of concentrations of Gβ1γ2 
was reconstituted in phospholipid vesicles, and concentration-dependent increases 
in PtdIns(4,5)P2 hydrolysis were observed with purified PLC-η2(PH-C2). Furthermore, 
addition of Gαi1 inhibited Gβ1γ2 activation of PLC-η2, and it did so in a 
concentration-dependent manner. The addition of GRK2-ct also reversed the 
activation of PLC-η2 by Gβ1γ2 to basal levels, and it did so in a 
concentration-dependent manner. Thus, Gβγ-mediated activation of PLC-η2 depends 
on the presence of free Gβγ. Preliminary data with purified PLC-η2(EF-C2) (a 
construct that eliminates PH domain and encompasses EF-hand repeats through the 
C2 domain) also exhibited Gβ1γ2 activation. Therefore, activation of PLC-η2 by this G 
protein heterodimer occurs at least in part through interaction with the catalytic core 
of the enzyme.  
In conclusion, my Ph.D. thesis work has illustrated the existence of a new isoform 
of PLC termed PLC-η2, and demonstrated that Gβ1γ2 directly activates this isoform in 
a mechanism depending on the presence of free Gβγ, suggesting PLC-η2 may in part 
function downstream of G-protein-coupled receptors. 
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Future experiments will delineate the region of Gβ1γ2 interaction and reveal the 
mechanism of activation. Previous studies have shown that Gβγ dimer interacts with 
multiple sites in PLC-β isozymes. The sites of interaction of PLC-β2 with Gβγ were 
mapped to 62 amino acid sequences (residues Leu580 to Val641) of PLC-β2 by 
testing GST fusion proteins comprising various PLC-β2 fragments in in vitro binding 
assays (163). Sankaran et al. narrowed down the interaction sites to the 20 amino 
acid sequences in the Y domain using peptide studies (164). In 1999 Wang et al. 
reported that membrane associated Gβγ also bound to the isolated PH domain of 
PLC-β2 using FRET (165). Furthermore, the PH domains of PLC-β2 and PLC-β1 
have similar affinity for Gβγ, which is much greater than that observed with the PH 
domain of PLC-δ1; a chimera comprised of the PH domain from PLC-β2 and the rest 
of PLC-δ1 were responsive to Gβγ regulation (166). It is clear that the PH domain of 
PLC-β2 interacts with Gβγ in an unknown mechanism to facilitate Gβγ regulation of 
PLC-β2. In a more recent study, Snyder et al. demonstrated that the PH domain of 
PLC-β2 is the putative effector site for Rac binding (147). Illenberger et al. 
demonstrated that the catalytic domain of PLC-β2 is necessary and sufficient for Gβγ 
stimulation, and the PH domain of PLC-β2 enhances Gβγ activation of PLC-β2 (146). 
Thus, the PH domain is absolutely required for Rac activation of PLC-β2; however, it 
only enhances Gβγ-mediated stimulation of PLC-β2.  
I suspect that the PH domain of PLC-η2 is not involved in Gβγ interaction. Not 
only did our preliminary data show Gβγ-promoted activation of PLC-η2(EF-C2), a 
construct lacking the PH domain, but further examination of the amino acid 
 118
sequences of PLC-η2 PH domain reveals that it contains key residues illustrated in 
PLC-δ1 PH to interact with phosphoinositides. The amino acids of the PH domain of 
PLC-δ1 that interact with Ins(1,4,5)P3 are mostly in the β1/β2 and β3/β4 loops. Direct 
hydrogen bonds are seen between the ligand Ins(1,4,5)P3 and seven amino acids 
(114). Two lysines, K30 and K57, make direct contacts with 4- and 5-phosphate 
groups of Ins(1,4,5)P3; R40, S55, R56 and E54 completely bury the 5-phosphate of 
Ins(1,4,5)P3; and K30, K32, K57 and T107 directly hydrogen bond with the 
4-phosphate of Ins(1,4,5)P3. Equivalent amino acid residues corresponding to K30, 
K32, S55, R56, K57 and T107 are found in the sequence of PLC-η2, which suggests 
that PLC-η2PH may exhibit similar affinity toward phosphoinositides. It will be 
important to examine the affinity of PLC-η2PH for Ins(1,4,5)P3 or PtdIns(4,5)P2 
compared to that of PLC-δ1PH. Moreover, a crystal structure of PLC-η2PH in 
complex with Ins(1,4,5)P3 would provide more insight into PH domain interaction with 
inositol phosphates in general. PLC-η isozymes have been implicated to function in 
neuronal development (83). Wild-type PLC-η1 was found to be 
membrane-associated but in the absence of PH domain was cytosolic (82). The 
significance of PLC-ηPH interaction with membrane lipids remains to be identified. 
Exactly how Gβγ dimer activates PLC-β2 remains unclear. We suspect that Gβγ 
dimers interact with PLC-β2 and recruit it to the membrane, but a Gβγ-induced 
conformational change in the active site cannot be ruled out. How Gβγ dimer interacts 
with different regions of the enzyme remains unclear. Gβγ dimer cannot 
simultaneously bind both the PH and Y domains of PLC-β2 because these two 
domains are clearly on the opposite planes in the crystal structure of Jezyk et al. (148) 
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and Hicks et al. (unpublished). We obviously do not know where Gβγ dimer interacts 
with PLC-η2. The fact that PLC-η2 PH domain is more similar to that of PLC-δ1 
suggests that the Gβγ dimer does not interact with PLC-η2 PH domain. It is likely that 
Gβγ makes contacts within the catalytic region of PLC-η2 and recruits it to the 
membrane. Whether Gβγ cause conformational changes in the catalytic region or X-Y 
linker region of PLC-η2 to increase lipid hydrolysis remains unexplored. 
A recent exciting observation made by Hicks et al. (unpublished) and Jezyk et al. 
(148) about the X-Y linker sequences of PLC-β has revealed another level of 
regulation of PLC isozymes. The X-Y linker was identified as a possible negative 
regulator of PLC activity from the crystal structure of PLC-β2. The linker sequences 
clamp over the catalytic pocket of PLC-β2 and apparently prevent it from accessing 
lipid substrate. The X-Y linker exhibits dense negative charges and upon membrane 
association is proposed to be repulsed away due to the electrostatic repulsion with 
the membrane lipids. Therefore the catalytic pocket is uncovered for substrate 
hydrolysis. Hicks et al. demonstrated that removal of the X-Y linker region sequences 
in PLC-β2, -δ1, and -ε, resulted in increased basal activity in in vivo transfection 
assays. Purified PLC-β2 and PLC-ε lacking the linker also exhibited constitutive 
activation, providing strong evidence for the validity of this hypothesis.  
Intrigued by above studies, the X-Y linker region sequences in PLC-η2 were 
examined and found to be quite opposite of those in other PLC isozymes. That is, the 
X-Y linker of PLC-η2 is essentially devoid of sequences containing dense negative 
charge and is overall positively charged. Thus, we hypothesize that the PLC-η2 X-Y 
linker would lead to membrane association due to electrostatic attraction to 
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phosphoinositide substrate-containing membrane surfaces. Thus, we anticipate 
PLC-η2 exhibits less autoinhibition than other PLC isozymes. This is also consistent 
with our observation of higher basal activity of PLC-η2. Nomikos et al. also reported 
that a dense positive region exists in the X-Y linker of PLC-ζ and that it is important 
for membrane association and activity of PLC-ζ (186). Similar patches of positive 
residues exist in the X-Y linker of PLC-η2, suggesting a similar function of the linker 
region between the two isozymes. Thus, the X-Y linker of PLC-η2 or PLC-ζ may 
function distinctly from that of PLC-β2, PLC-δ1, or PLC-ε. We hypothesize that 
removal of the X-Y linker sequences in PLC-η2 would lead to decreases in PLC-η2 
basal activity. Our preliminary data has suggested that such a hypothesis is correct; 
however, further verification is needed. Besides its contribution to the basal activity of 
PLC-η2, how the X-Y linker of PLC-η2 interacts with the substrate pocket and its role 
during Gβ1γ2 activation remain to be defined. 
The overall charge of PLC-η2 protein is positive, whereas that of other PLC 
isozymes is fairly neutral. Moreover, the PH domain of PLC-η2 is also overall 
positively charged, whereas both that of PLC-β2 and PLC-δ1 are nearly neutral. 
Whether this observation is significant in the physiological functions of PLC-η2 
remains to be answered. 
 Although lacking functional data, Stewart et al. first identified two putative PLC-η 
sequences in early 2005 (84). Soon after, both Hwang et al. and Nakahara et al. 
claimed PLC-η to be a neuron-specific isozyme and implicated the importance of 
PLC-η in the formation and/or maintenance of the neuronal network in the postnatal 
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brain. 
Nakahara et al. reported cloning of mouse PLC-η2 from mouse brain with a 
predicted molecular weight of 125 kDa (83), corresponding to a splice variant 
(21b/22/23) identified in our study. They found this form of PLC-η2 expresses 
restrictively in mouse brain both by western blot and northern blot analysis. The 
authors also examined PLC-η2 expression during various developmental stages of 
mouse brain. PLC-η2 expression was first detected at 2 weeks after birth, and 
gradually increased during brain development, similar to the expression pattern for a 
marker of mature oligodendrocytes, MBP. PLC-η2 specifically locates in 
hippocampus, cerebral cortex, and olfactory bulb of the brain by both western and in 
situ hybridization analysis. However, PLC-η2 expression was not detected in the 
olfactory epithelium or vomeronasal organs where odor and pheromone receptors 
exist, although it was abundantly expressed in main and sub olfactory bulbs. These 
results suggest that PLC-η2 is not likely coupled to odor or pheromone receptors, but 
is somehow involved in odor or pheromone signal transduction. The authors also 
claimed PLC-η2 to be specifically expressed in neurons, but not in astrocyte-enriched 
cultures. However, we observed that one splice form of PLC-η2 is endogenously 
expressed in human 1321N1 cells.  
Hwang et al. reported cloning of the PLC-η1 gene containing at least 25 exons 
(82). Three splice variants of PLC-η1 (both human and mouse) were identified and 
splicing occurred at exons 23, 24, and 25, similar to the case of PLC-η2. PLC-η1 was 
found most abundantly expressed in brain, and also in lung although the protein level 
of PLC-η1 in lung was barely detectable. In situ hybridization was performed and 
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PLC-η1 was found to be expressed throughout the whole brain, especially in the 
inner layer of the olfactory bulb, CA region, hippocampus, Purkinje layer, cerebral 
cortex, hypothalamus, etc, which are neuronal cell-enriched regions, suggesting 
PLC-η1 plays a role in neuron-specific signal transduction.  
Studies on PLC-η expression suggest a role for this novel enzyme in brain during 
developmental stages which poses a question of what the physiological regulators of 
PLC-η are in brain. Does Gβγ regulation of PLC-η2 contribute to any processes 
involved in brain development? What are other activators or regulators of PLC-η2 or 
PLC-η1 in olfactory bulbs? What is the role of PLC-η2 in odor or pheromone signal 
transduction? PLC-η2 null mice will not answer all of the questions, but will provide 
insight into the physiological roles of PLC-η2. PLC-η contains a long carboxyl 
terminus containing a class II PDZ-binding motif. Whether this motif facilitates 
interaction between PLC-η enzyme and other unknown signaling proteins still 
remains unexplored. Identifying interacting proteins of PLC-η may help delineate 
pathways of PLC-η regulation and its physiological functions. Our preliminary results 
suggested differential regulation of PLC-η2 versus PLC-η1 by Gβγ. Further 
experiments are needed to elucidate Gβγ regulation of PLC-η and its relevant 
biological roles.  
It is worthwhile to mention that human PLC-η2 locates on chromosome 1p.36.32 
which is very near the telomere region of the chromosome 1. Sequences at this end 
of the chromosomes are often deleted in diseases of cancer and neurodegeneration 
(214-216). It is not known whether PLC-η2 plays a role in such diseases, although 
many of its ESTs are from neuroblastoma and retinoblastoma 
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(http://www.genome.ucsc.edu). 
 In conclusion, this thesis work has resulted in the cloning of PLC-η2 and has 
identified Gβγ subunits of heterotrimeric G-proteins as direct activators of this 
isozyme. At least 13 different PLC isozymes exist in mammalian tissues, but our 
knowledge of their relative roles remains rudimentary. As we increasingly realize the 
important roles played by various membrane phosphoinositides in cell signaling in 
addition to their historically considered function as precursors of Ins(1,4,5)P3 and 
DAG, it is imperative to unravel the functions of PLC-η2 and other PLC isozymes at 
the cellular and mechanistic levels. 
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APPENDIX – Alignment of PLC Isozymes 
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